THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES

A subject-matter of the invention is the use of quinazolinedione derivatives as medicaments or for manufacturing a medicament intended for the treatment and/or prevention of disorders related to the central nervous system (abbreviated CNS) and/or related to the peripheral nervous system (abbreviated PNS). The invention relates more particularly to the use of quinazolinedione derivatives as medicaments or for manufacturing a medicament intended for the treatment and/or prevention of psychiatric disorder(s) and/or intended for the treatment and/or prevention of neurological disorder(s).

The central nervous system or CNS comprises the brain, the spinal cord and the cranial nerves.

The peripheral nervous system or PNS is the part of the nervous system formed of ganglions and nerves which brings about the movement of information between the organs and the central nervous system or CNS and which carries out the motor commands of the latter. It comprises the somatic nervous system and the autonomic nervous system.

The invention relates to quinazolinedione derivatives which are inhibitors of phosphodiesterase 7 (PDE7). Some of these derivatives also inhibit phosphodiesterase 8 (PDE8).

Phosphodiesterases (PDEs) are intracellular enzymes responsible for the hydrolysis of cAMP (cyclic adenosine 3',5'-monophosphate) and cGMP (cyclic guanosine 3',5'-monophosphate) secondary messengers to give inactive 5'-monophosphate nucleotides. cAMP and cGMP play an essential role in cell signalling pathways and are involved in numerous physiological processes.

The inhibition of phosphodiesterases is reflected by an increase in intracellular concentrations of cAMP and cGMP, resulting in the specific activation of phosphorylation pathways involved in varied functional responses. The increase in the intracellular concentrations of cAMP or of cGMP using selective inhibitors of phosphodiesterases appears to be a promising approach in the treatment of various diseases (Bender and Beavo, Pharmacol. Rev., (2006) 58, 488-520). The inhibitors of phosphodiesterases are thus of interest as therapeutic agents and as pharmacological tools.

To date, eleven families of phosphodiesterases have been identified. They are distinguished by their primary structure, their substrate specificity and their sensitivity with regard to various effectors and inhibitors specific for PDEs. Each family is composed of one or more genes which are expressed in various tissues in the form of splicing variants (Bender and Beavo, Pharmacol. Rev., (2006) 58, 488-520; Lugnier, Pharmacol.

Therapeut., (2006) 109, 366-398).

PDE4, PDE7 and PDE8 specifically hydrolyse cAMP and PDE5, PDE6 and PDE9 specifically hydrolyse cGMP.

The family PDE7 is represented by the isoforms PDE7A and PDE7B originating from two distinct genes.

Human PDE7A (Michaeli et al., J. Biol. Chem., (1993) 268, 12925-12932; Han et al., J. Biol. Chem., (1997) 272, 16152-16157; Wang et al., Biochem. Biophys. Res. Commun., (2000) 276, 1271-1277) and human PDE7B (Sasaki et al., Biochem. Biophys. Res. Commun., (2000), 271, 575-583; Gardner et al., Biochem. Biophys. Res. Commun., (2000) 272, 186-192) selectively hydrolyse cAMP with Michaelis constants (Km) of 0.1 to 0.2 μM and 0.13 to 0.2 μM respectively. The catalytic part of PDE7B exhibits approximately 67% homology with that of PDE7A.

Three splicing variants are known for PDE7A. PDE7A1 and PDE7A3 are expressed mainly in the cells of the immune system and of the lungs, while PDE7A2 is above all expressed in the muscles of the skeleton, the heart and the kidneys. For PDE7B, three variants have also recently been identified (Giembycz and Smith, Drugs Future, (2006) 31, 207-229).


The tissue distribution profiles for PDE7A and PDE7B are very different, suggesting that these two isoforms have distinct functions from the physiological viewpoint. While PDE7A is copiously expressed in haematopoietic cells, the lungs, the placenta, Leydig cells, the spleen, the collecting tubes of the kidneys, and the adrenal glands, strong expression of PDE7B is detected in the pancreas, the heart, the thyroid and the muscles of the skeleton (Giembycz and Smith, Drugs Future, (2006) 31, 207-229). However, coexpression of the messenger RNAs (mRNAs) of PDE7A and PDE7B is observed in some tissues. This is the case in the osteoblasts (Ahlstrom et al., Cell Mol. Biol. Lett., (2005) 10, 305-319) and in some regions of the brain: several areas of the cortex, the dentate gyrus, the majority of the components of the olfactory system, the striatum, numerous nuclei of the thalamus and the pyrimidal cells of the hippocampus (Miro et al., Synapse, (2001) 40, 201-214; Reyes-Irisarri et al., Neuroscience, (2005) 132, 1173-1185). In contrast, in some areas of the brain, only one of the two isoforms is expressed. Thus, only the mRNAs of PDE7A are present in many nuclei of the brain stem. Likewise, the mRNAs of PDE7B are present at high concentrations in the nucleus accombens and the dorsal motor nucleus of the vagus nerve, while the mRNAs of PDE7A are not detected there (Miro et al., Synapse, (2001) 40, 201-214; Reyes-Irisarri et al., Neuroscience, (2005) 132, 1173-1185).

The document WO2008/119057 describes a method for the treatment of movement anomalies associated with a neurological movement disorder pathology, such

as Parkinson's disease, the treatment method comprising the administration to a patient of an amount of an agent which is an inhibitor of PDE7 which is effective in inhibiting the enzymatic activity of PDE7.

A subject-matter of the present invention is in particular therapeutic applications of quinazolinedione derivatives, which may prove to be powerful inhibitors of PDE7, or of PDE7 and of PDE8, according to the derivatives.

The invention relates to the use of a compound corresponding to the following general formula (I):



(I)

in which

— A represents an aryl group or a heteroaryl group;

— R_1 represents:

- a hydrogen atom,
- -C(O)R in which R is a hydrogen atom, a (C_1-C_6) alkoxy group, an aryl group, a (C_3-C_6) cycloalkyl group or a (C_1-C_6) alkyl group, the said alkyl optionally being substituted by:
  - . one or more hydroxyl group(s),
  - . a benzyloxy group,
  - . a (C_1-C_6) alkoxy group, optionally substituted by an aryl, or
  - . a (C_3-C_6) cycloalkyl group,
- an optionally substituted (C_1-C_6) alkyl group;

— R_2 represents:

- a hydrogen atom,
- a halogen atom,

■ a cyano group,

■ a nitro group,

■ a (C_1-C_6) alkyl group optionally substituted by an $-NH_2$ or else by an -NHC(O)Rb group, with Rb as defined below,

■ an -ORa group in which Ra represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s),

. a (C_2-C_6) alkynyl group,

. an aryl group;

— R_3 represents:

■ a hydrogen atom,

■ a halogen atom,

■ a hydroxyl group,

■ a cyano group,

■ an $-SCF_3$ group,

■ a nitro group,

■ an oxo group,

■ an $-S(O)_{0-2}$-alkyl group, an $-S(O)_{0-2}$-heterocycloalkyl group, an $-O-SO_2$-aryl group optionally substituted by one or more halogen atom(s);

■ an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl,

■ an optionally substituted sulphonamide group,

■ an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C_1-C_6) alkyl group, by one or more halogen atom(s) or by a (C_1-C_6) alkoxy group,

■ a heterocycloalkyl group optionally substituted by a (C_1-C_6) alkyl group,

■ a (C_1-C_6) alkyl group optionally substituted by:

- one or more halogen atom(s),

- an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s),

- a heteroaryl group,

- one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or

- a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by

a (C_1-C_6) alkyl group, Ra being as defined above,

- a -C(O)NRbRc group, with Rb and Rc being as defined below,
- a -C(O)ORc group or an –O-C(O)ORc group, with Rc being as defined below,
- a (C_1-C_6) alkoxy group, optionally substituted by
  - an aminoalkyl group,
  - an aminocycloalkyl group,
  - a cycloalkyl group,
  - a heterocycloalkyl group,
  - a monocyclic or polycyclic heteroaryl group,
  - one or more hydroxyl group(s),
  - one or more halogen atom(s),
  - a (C_1-C_6) alkoxy group,
  - a –C(O)ORc group, with Rc being as defined below,
  - a -C(O)NRbRc group, with Rb and Rc being as defined below,
  - an oxo group, and/or
  - an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C_1-C_6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group,
- an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by
  - an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C_1-C_6) alkyl group,
  - an oxo group,
  - one or more halogen atom(s), and/or
  - a (C_1-C_6) alkyl group, which can itself be substituted by an aryl group and/or an oxo group,
- an –NH-CO-NH-aryl group, an –NH-CO-NH-heteroaryl group or an –NH-CO-NH-(C_1-C_6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C_1-C_6) alkoxy group,
- an –N-(C_1-C_6) alkyl group, it being possible for the (C_1-C_6) alkyl group to be substituted by
  - one or more oxo group(s), and/or
  - one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO_2 group,
- an –NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s);

or else R_3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C_1-C_6) alkoxy group or a (C_1-C_6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s);

— R_4 represents a hydrogen atom, an oxo group or a (C_1-C_6) alkyl group;

— Rb represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl, cyano, amino, heterocycloalkyl or (C_1-C_6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s),

. a (C_3-C_6) cycloalkyl group,

. a (C_2-C_6) alkynyl group,

. a (C_1-C_6) alkoxy group,

. an aryl group optionally substituted by one or more halogen atom(s);


— Rc represents a hydrogen atom or a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s);

or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group;

— m and n represent, independently of one another, the value 0, 1 or 2, it being understood that $m+n \leq 3$;

— p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R_2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R_3 groups are on separate carbon atoms and can be different from one another;

— q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type:



with R_1, R_4, m and n as defined above,

— r represents the value 0 or 1,

as medicament or in the preparation of a medicament intended for the treatment and/or prevention of disorders related to the central nervous system and/or related to the peripheral nervous system.

According to one embodiment, the said disorders are chosen from psychiatric disorders and neurological disorders.

The compounds of general formula (I) can comprise one or more asymmetric carbons. They can thus exist in the form of enantiomers or of diastereoisomers. These enantiomers or diastereoisomers, and their mixtures, including racemic mixtures, come within the invention.

Due to their structure, the compounds of general formula (I) can also exist in the form of isomers of rotamer or atropisomer type.

The compounds of formula (I) can also exist in the form of bases or addition salts with acids. Such addition salts come within the invention.

These salts are advantageously prepared with pharmaceutically acceptable acids but the salts of other acids, for example of use in the purification or separation of the compounds of general formula (I) also come within the invention.

The compounds of general formula (I) can also occur in the crystalline, amorphous or oily form, these forms coming within the invention.

The compounds of general formula (I) can in addition occur in the form of hydrates or of solvates, namely in the form of combinations or of associations with one or more molecules of water or with a solvent. Such hydrates and solvates also come within the invention.

According to the present invention, the N-oxides of the compounds comprising an amine also come within the invention.

The compounds of formula (I) in accordance with the invention also comprise those in which one or more hydrogen, carbon or halogen, in particular chlorine or

fluorine, atoms have been replaced by their radioactive isotopes, for example tritium, in order to replace hydrogen, or carbon-14, in order to replace carbon-12. Such labelled compounds are of use in research, metabolism or pharmacokinetic studies or in biological and pharmacological assays as tools.

In the context of the invention, the following definitions apply:

- in (C_1-C_6), the numerical indices determine the possible number of carbon atoms present in a chain or a ring. Thus, by way of example, C_1-C_6 represents a carbon chain which can have from 1 to 6 carbon atoms. Likewise, by way of example, (C_1-C_5) represents a carbon chain which can have from 1 to 5 carbon atoms or also (C_3-C_6) can represent a saturated carbon ring which can have from 3 to 6 carbon atoms;

- alkoxy: an -O-alkyl group comprising a saturated, linear or branched, aliphatic chain;

- alkynyl: a mono- or polyunsaturated, linear or branched, aliphatic group comprising, for example, one or two acetylenic unsaturations. For example, a (C_2-C_6) alkynyl group can represent an ethynyl, propynyl, and the like;

- alkyl: a saturated, linear or branched, aliphatic group; for example, a (C_1-C_6) alkyl group represents a linear or branched carbon chain of 1 to 6 carbon atoms, in particular a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl or pentyl;


- aminoalkyl: an -NH(C_1-C_6) alkyl or also –N((C_1-C_6) alkyl)$_2$ group;

- aryl: an optionally substituted monocyclic aromatic system comprising from 5 to 14 members per ring, preferably from 5 to 10 members per ring. Mention may be made, as examples of monocyclic aryl groups, of phenyl or naphthyl; the aryl group can be substituted by a group which can be one or more halogen atom(s), a hydroxyl group, a cyano group, a trifluoromethylthio group, a nitro group, an alkyl group, an alkoxy group, an alkylthio group, a methylsulphonyl group, an alkylaminoalkyl group or alkylaminocycloalkyl group which is optionally substituted, an alkylaminoalkoxy or cycloalkylaminoalkoxy group or a sulphonamide group, for example:

- polycyclic aryl: an optionally substituted polycyclic aromatic system comprising from 5 to 14 members per ring, preferably from 5 to 10 members per ring, and comprising from 2 to 10 rings, at least one of the rings of which is aromatic. Mention may be made, as examples of polycyclic aryl groups, of aceanthrylene, anthracene, azulene, coronene, rubicene or naphthalene; the polycyclic aryl group can be substituted by a group which can be one or more halogen atom(s), a hydroxyl group, a cyano group, a trifluoromethylthio group, a nitro group, an alkyl group, an alkoxy group, an alkylthio group, a methylsulphonyl group, an alkylaminoalkyl or alkylaminocycloalkyl group which is optionally substituted, an alkylaminoalkoxy or cycloalkylaminoalkoxy group or a

sulphonamide group, for example;

- a bridged ring: a bicyclic structure comprising, according to the invention, a nitrogen atom, in which at least two carbon atoms are connected via a single bond or a carbon chain which can comprise 2 carbon atoms. By way of example, the abovementioned ring is of the type:



with q = 1 or 2 and with the other groups and indices as defined above;

- cycloalkyl: a saturated cyclic aliphatic group comprising from 3 to 8 carbon atoms. Mention may be made, by way of example, of a cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group;

- halogen: a fluorine, a chlorine, a bromine or an iodine;

- haloalkyl: (C_1-C_6) alkyl substituted by one to three halogen atom(s);

- heteroaryl: a monocyclic aromatic system comprising from 5 to 14 ring members, preferably from 5 to 10 ring members, and comprising one to several heteroatoms, such as nitrogen, oxygen or sulphur atoms. The nitrogen atoms can be in the form of N-oxides. For example, a monocyclic heterocycle can be a pyran, a pyrazine, a pyrazole, a pyridazine, a pyridine, a pyrimidine, a pyrrole, an isothiazole, an isoxazole, a furan, an imidazole, a morpholine, a thiophene, a piperazine, a diazetidine, a dihydropyrrolidine, a piperidine, an azepine, and the like; a bicyclic heterocycle can be an isoquinoline, a pteridine, a chroman, and the like; a tricyclic heterocycle can be a phenanthroline, a xanthene, and the like;

- polycyclic heteroaryl: an optionally substituted polycyclic aromatic system comprising from 5 to 14 members per ring, preferably from 5 to 10 members per ring, and comprising from 2 to 10 rings, additionally comprising one to several heteroatoms, such as nitrogen, oxygen or sulphur atoms, in at least one of the rings, and at least one of the rings of which is aromatic. Mention may be made, as examples of polycyclic heteroaryl groups, of indole, benzofuran, benzimidazole, benzothiophene, benzotriazole, benzothiazole, benzoxazole, quinoline, isoquinoline, indazole, quinazoline, phthalazine,

quinoxaline, naphthyridine, 2,3-dihydro-1H-indole, 2,3-dihydrobenzofuran, 2,3-dihydro-indene, tetrahydroquinoline, tetrahydroisoquinoline or tetrahydroisoquinazoline;

- a heterocycloalkyl: an optionally substituted saturated ring comprising from 3 to 8 atoms and comprising one to several heteroatoms, such as nitrogen, oxygen or sulphur atoms, in at least one of the rings, or several heteroatoms which are identical to or different from one another. For example, a heterocycloalkyl can be a pyrrolidine, a morpholine, a piperazine, a diazetidine, a dihydropyrrolidine, a piperidine, a piperadine, an azepane, an imidazolidine, a thiomorpholine, a tetrahydropyran, a tetrahydrothiopyran, a piperazine, a diazepane, and the like;
- hydroxyl: an -OH group;
- nitro: an $-NO_2$ group;
- oxo: a -C(O)- group;
- sulphonamide: group corresponding to the formula SO_2-N-alkyl or SO_2-N-cyclo-alkyl, alkyl and cycloalkyl being as defined above;
- trifluoromethylthio is defined by the formula $-S-CF_3$.

Furthermore, it is understood that, in the present description, when an atom or a group is substituted or optionally substituted by one or more defined group(s) or atom(s), the substituents can be identical to or different from one another and may be carried, if appropriate, by the same atom or different atoms.

Mention may be made, among the compounds which are a subject-matter of the invention, of a group of compounds of formula (I) in which A represents an aryl group, in particular a phenyl or heteroaryl group, in particular a pyridyl group, and all the other substituents and indices are as defined in the general formula (I) defined above.

Mention may be made, among the compounds in accordance with the invention, of a group of compounds of formula (I) in which q = 0, m and n each represents 1, and all the other substituents and indices are as defined in the general formula (I) defined above.

Mention may be made, among the compounds in accordance with the invention, of a group of compounds of formula (I) in which R_2 represents a (C_1-C_6) alkyl group, in particular a methyl, substituted by an -NHC(O)Rb group in which Rb and the other substituents and indices are as defined for the compound of general formula (I) defined above.

Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which R_2 represents an -ORa group, the Ra

group and all the other substituents and indices being as defined in the general formula (I) defined above.

Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which R_2 is a halogen atom or a cyano or a hydrogen or a hydroxyl or a (C_1-C_6) alkyl optionally substituted by an -NH_2, or else by an -NHC(O)Rb group, Rb and the other substituents and indices being as defined in the general formula (I) defined above.

Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which A is a phenyl, R_1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, and R_2 represents -ORa, Ra and the other substituents and indices being as defined in the general formula (I) defined above.

Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which A is a phenyl, R_1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p is equal to 2, one of the R_2 groups is -ORa and the other of the R_2 groups is a halogen atom, Ra and the other substituents and indices being as defined in the general formula (I) defined above.

Mention may be made, among the compounds in accordance with the invention, of a group of compounds of general formula (I) in which A is a phenyl, R_1 is a -C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p = 1 and R_2 is a methyl substituted by an -NH-CO-Rb group, Rb and the other substituents and indices being as defined in the general formula (I) defined above.

Advantageously, in the compounds of formula (I), the R_2 group is in the 6 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system. The compounds of formula (I) can also have an R_2 group in the 7 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system. The R_2 groups in the 6 and 7 positions can be identical or different.

Advantageously, in the compounds of formula (I), p is equal to 1 or 2.

The compounds of general formula (I) can be in the base, hydrate or solvate form, in the form of isomers or in the form of their mixtures.

In a specific form, when p' = 2, then the two R_3 groups are in the 3 and 4 positions of the ring system A and can be different from one another.

The combinations of the groups of compounds in accordance with the invention mentioned above also come within the invention.

Mention may be made, as examples of preferred compounds in accordance with the invention, of the following compounds:

No. 1: 2-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}propanenitrile

No. 2: 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline-2,4(1H,3H)-dione

No. 3: {[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile

No. 4: 2-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}propanenitrile

No. 5: {[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile

No. 11: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 12: 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione

No. 13: 4-[3-(3,4-dimethoxybenzyl)-2,4-dioxo-6-(2,2,2-trifluoroethoxy)-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 14: 1-(1-acetylpiperidin-4-yl)-6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione

No. 16: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 20: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide

No. 22: 1-(1-acetylpiperidin-4-yl)-6-(aminomethyl)-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione hydrochloride

No. 23: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}formamide

No. 24: N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}formamide

No. 25: N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide

No. 32: 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 33: 4-[3-(3,4-dichlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 34: 4-[3-(4-chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 35: methyl 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]methyl}benzoate

No. 36: 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]methyl}benzoic acid

No. 37: 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]methyl}-N-(2-methoxyethyl)benzamide

No. 38: 4-[3-(3,4-dimethoxybenzyl)-6-methyl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 39: 4-[6-(2,2-difluoroethoxy)-3-(3-hydroxy-4-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 40: 4-[6-(2,2-difluoroethoxy)-3-[3-(2-hydroxyethoxy)-4-methoxybenzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 41: 4-[6-(2,2-difluoroethoxy)-3-(3-ethoxy-4-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 42: 4-[6-(2,2-difluoroethoxy)-3-[4-methoxy-3-(2-methoxyethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 43: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]azepane-1-carbaldehyde

No. 47: 4-[6-(2,2-difluoroethoxy)-3-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 48: 4-[5-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 49: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 50: 2-(5-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-

dihydroquinazolin-3(2H)-yl]methyl}-2-methoxyphenoxy)acetamide

No. 51: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]-3-methylpiperidine-1-carbaldehyde

No. 52: 3-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]-8-azabicyclo[3.2.1]octane-8-carbaldehyde

No. 56: 4-{3-[4-(cyclopentyloxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 57: 4-[3-(3-chlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 58: 4-[3-(4-chlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 59: 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 72: 4-[3-(3,4-dimethoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 74: 4-[3-(3,4-dichlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 76: 4-{3-[(6-chloropyridin-3-yl)methyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 78: 4-[3-(3-chloro-4-methoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 79: 4-[3-(3,4-dimethoxybenzyl)-6-(2-fluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 89: 2-[5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]acetamide

No. 90: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-hydroxy-4-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 91: 4-[3-(3,4-dimethoxybenzyl)-6-ethoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 97: 4-[5,7-dichloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 102: 4-[7-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 108: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-fluoro-4-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 111: 4-[6-(difluoromethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 112: 4-[3-(3,4-dimethoxybenzyl)-6-(1-methylethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 114: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-methoxy-3-(1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 116: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 117: 4-{3-[3,5-bis(trifluoromethyl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 118: 4-[3-(3-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 124: 4-{3-[3-chloro-4-(2-methoxyethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 130: 4-[3-(3,4-diethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 131: 4-[3-(4-ethoxy-3-methoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 133: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-methoxy-3-methylbenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 134: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 135: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 143: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 145: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-nitrobenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 155: 4-[3-(4-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 158: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(morpholin-4-ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 160: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-morpholin-4-ylbenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 165: 4-[3-(biphenyl-4-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 166: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(methylsulphanyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 167: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-3-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 170: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-methylbenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 175: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]acetamide

No. 178: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-propoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 183: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N-methylacetamide

No. 184: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N,N-dimethylacetamide

No. 185: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N-methoxy-N-methylacetamide

No. 186: 4-{3-[4-(cyclopentyloxy)-3-ethoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 188: 4-{3-[4-(cyclopentyloxy)-3-(1-methylethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 189: 4-{3-[4-(cyclopentyloxy)-3-propoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 190: 4-{3-[4-(cyclopentyloxy)-3-hydroxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 193: 4-{3-[4-(difluoromethoxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 194: 4-{3-[4-(difluoromethoxy)-3-ethoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 200: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-3-yl)-benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 201: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-4-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 203: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-1H-indol-6-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 206: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 207: 2-[4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]-N-methylacetamide

No. 212: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1H-pyrazol-1-yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 213: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-2-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 215: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2-yl)-benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 216: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(quinolin-7-ylmethyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 218: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-methoxynaphthalen-2-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 223: 4-{3-[4-(1H-benzimidazol-1-yl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 224: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 226: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(tetrahydrofuran-3-yloxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 228: 4-[3-{4-[(1-benzylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 230: 4-[3-(1-benzothiophen-5-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 232: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 233: 4-[3-(3,4-dimethoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 234: 4-[3-{4-[(1-acetylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 239: 4-[3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 240: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 242: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 243: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-(thiophen-3-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 245: 4-[3-(4-ethoxy-3-methoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 246: 4-[3-{4-[2-(2,3-dihydro-1H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 250: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 251: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2-(piperidin-1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 254: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 258: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(hydroxymethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 263: (2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid

No. 264: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-(thiophen-2-yl)-1H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 270: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 275: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 276: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-phenyl-1H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 278: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1H-pyrazol-1-yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 279: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-(thiophen-2-yl)pyrimidin-5-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 280: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(1-methyl-1H-pyrazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 282: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(3-methyl-1,2,4-oxadiazol-5-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 283: [2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]acetic acid

No. 285:4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(thieno[2,3-b]pyridin-2-

ylmethyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 286: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-phenylpyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 287: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-(morpholin-4-yl)pyridin-3-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 289: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2-yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 292: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-5-phenyl-1H-pyrazol-3-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 294: 4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile

No. 295: (2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N-methylpropanamide

No. 297: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 298: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(morpholin-4-ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 299: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(piperidin-1-ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 300: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazoiin-1(2H)-yl]piperidine-1-carbaldehyde

No. 301: 2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N-ethylacetamide

No. 302: (2S)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid

No. 305: 4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[(3R)-2-oxo-1-phenylpyrrolidin-3-yl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 306: 4-{3-[4-(cyclobutylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 307: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 308: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-hydroxy-3-

methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 309: 4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 310: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 311: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 312: 4-[3-(4-ethoxy-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 315: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(3-methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 316: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(2-fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 317: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(4-fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 318: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(4-methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 319: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2-yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 320: 4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 321: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(1-methyl-1H-pyrazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 322: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 323: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-(thiophen-2-yl)-1H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 324: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2-(piperidin-1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 325: 4-[3-{4-[2-(2,3-dihydro-1H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 326: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 327: 4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 328: 4-[3-{[6-(3,5-dichlorophenyl)pyridin-3-yl]methyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 329: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile

No. 330: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1H-pyrazol-1-yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 331: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(3-fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 332: 3-[5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)pyridin-2-yl]benzonitrile

No. 333: 4-[3-(3,4-diethoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 334: 4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 335: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(morpholin-4-ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 336: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1H-pyrazol-1-yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 337: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)-benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 338: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-propoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 339: 4-{3-[4-(1H-benzimidazol-1-yl)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 340: 5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxybenzonitrile

No. 341: 3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carbonitrile

No. 342: 4-[3-(4-bromobenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 343: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-methoxyethoxy)benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 344: 4-{3-[4-(benzyloxy)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 345: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-ethoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 349: 4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-fluoroethoxy)benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 350: 4-[3-{4-[(2-chloro-4-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 351: 4-[3-{4-[(2,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 352: 4-[3-{4-[(2-chloro-6-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 353: 4-[3-{4-[(2,6-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 354: 4-[3-{4-[(2-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 355: 4-[7-fluoro-3-{4-[(2-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 357: 2-[(3,4-dichlorobenzyl)oxy]-5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzonitrile

No. 358: 4-[3-{4-[(3,4-dichlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 360: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(2-phenylethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 362: 4-[3-{4-[(4,5-dichloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 369: 4-[3-{4-[(4-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-

(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 371: 4-[3-{3-chloro-4-[(4-chlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 373: 4-[3-{3-chloro-4-[(2,4-dichlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 375: 4-[7-fluoro-3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 376: 4-[3-{4-[(3,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 377: 4-[3-(4-{[4-chloro-3-(trifluoromethyl)benzyl]oxy}-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 379: 4-[3-{4-[(3-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 380: 4-[3-{4-[(3,5-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 381: 4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 382: 4-[3-{4-[(3-chloro-5-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 383: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[4-(trifluoromethyl)benzyl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 384: 4-[3-{4-[(2,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 385: 4-{[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]methyl}benzonitrile

No. 386: 3-{[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]methyl}benzonitrile

No. 387: 4-[3-{4-[(4-chloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 388: 4-[3-{4-[1-(3,4-dichlorophenyl)ethoxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 389: 4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{4-[(3-hydroxybenzyl)oxy]-3-methoxybenzyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 390: 4-[7-fluoro-3-{4-[(3-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 391: 4-[3-{4-[(3,4-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde

No. 392: 4-{3-[4-(5,6-dichloro-1H-benzimidazol-1-yl)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde

No. 393: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenyl 3,4-dichlorobenzenesulphonate

No. 394: 4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl 3,4-dichlorobenzene-sulphonate

No. 403: 3,4-dichloro-N-[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl]benzamide

The compounds in accordance with the invention can be prepared by the methods illustrated in the following Schemes 1 to 4.

In that which follows, the term "leaving group" is understood to mean a group which can be easily substituted, with departure of an electron pair, by cleavage of a heterolytic bond. This group can thus be easily replaced by another group, for example during a substitution reaction. Such leaving groups are, for example, halogens or an activated hydroxyl group, such as a mesylate, tosylate, triflate, and the like. Examples of leaving groups and references for their preparation are given in "Advanced Organic Chemistry", J. March, 3rd Edition, Wiley Interscience, pp. 310-316.

The term "protective group PG" is understood to mean a group which makes it possible to prevent the reactivity of a function group or position during a chemical reaction which may affect it and which restores the molecule after cleavage according to methods known to a person skilled in the art.

The term "temporary protective group for amines or alcohols" is understood to mean the protective groups such as those described in Protective Groups in Organic Synthesis, Greene T.W. and Wuts P.G.M., published by Wiley Intersciences, 1999, and

in Protecting Groups, Kocienski P.J., 1994, Georg Thieme Verlag.

Mention may be made, for example, of temporary protective groups for amines: benzyls or carbamates (such as *tert*-butoxycarbonyl, cleavable in an acid medium, or benzyloxycarbonyl, cleavable by hydrogenolysis), temporary protective groups for carboxylic acids: hydrogenolysable alkyl esters (such as methyl or ethyl or *tert*-butyl esters which can be hydrolysed in a basic or acid medium) and benzyl esters, temporary protective groups for alcohols or phenols, such as tetrahydropyranyl, methyloxymethyl or methylethoxymethyl, *tert*-butyl and benzyl ethers, or temporary protective groups for carbonyl derivatives, such as linear or cyclic acetals, such as, for example, 1,3-dioxan-2-yl or 1,3-dioxolan-2-yl; and reference may be made to the well known general methods described in Protective Groups, cited above.

A person skilled in the art will be in the position to choose the appropriate protective groups according to the circumstances. The compounds of formula (I) can comprise precursor groups for other functional groups which are generated subsequently in one or more other stages.

In the general synthetic schemes which follow, the starting compounds and the reactants, when their method of preparation is not described, are commercially available or are described in the literature or else can be prepared according to methods which are described therein or which are known to a person skilled in the art.

The pure enantiomers of the compounds in accordance with the invention can be obtained from enantiomerically pure precursors or else by chiral phase chromatography or else, when the compounds comprise acid or amine functional groups, by selective crystallizations of diastereoisomeric salts obtained by reaction of the compounds (I) with chiral amines or chiral acids respectively.

The compounds of general formula (I) can be obtained according to the following Schemes 1 to 4. Out of concern for clarity, the group R_4 has been chosen as being a hydrogen, p and p' represent 1 and 2 respectively and the R_2 and R_3 groups have been set as indicated in the schemes. However, it is to be understood that R_4 can be as defined in the general formula (I), and R_2 and R_3 can have the positions indicated in the general formula (I) and that p and p' can be as defined in the general formula (I).


The synthetic routes described below serve solely as illustration and are under no circumstances limiting. A person skilled in the art can apply without difficulty the teaching below to the compounds of formula (I) for which R, R_1, R_2, R_3, R_4, Ra, Rb, Rc, m, n, p, p' and q are as defined in the general formula (I).

According to Scheme 1, the compound of formula (IV) is obtained by a reductive

amination reaction by reacting a compound of formula (II), in which R' represents a (C_1-C_6) alkyl group and R_2 is as defined for the compound of formula (I) with a compound of formula (III) in an acid medium and in the presence of a reducing agent, such as sodium triacetoxyborohydride. The PG group of the compound of formula (III) is a protective group for the amine functional group which may advantageously be tert-butoxycarbonyl (boc). The compound of formula (IV) thus formed is subsequently acylated, according to methods well known to a person skilled in the art, with an alkyl or aryl chloroformate to give the compound of formula (V) in which R" represents a (C_1-C_6) alkyl group or an aryl group which is substituted. A hydrolysis reaction in a basic medium makes it possible to obtain the compounds of formula (VI) which, by a coupling reaction with a compound of formula (VII), in which R_3 is as defined for the compound of formula (I), results in the compounds of formula (VIII). An intramolecular cyclization reaction in the basic medium makes it possible to obtain the quinazolinedione derivatives of formula (IX). The protective group PG for the amine functional group is subsequently cleaved, for example in acid medium when PG is a boc, to give the compounds of formula (Ia) which give, by an acylation reaction, the compounds of formula (Ib).

The compounds of formula (Ia) are compounds of formula (I) and can act as intermediate for other compounds of formula (I), such as the compounds of formula (Ib).


Scheme 1



The compounds of formula (I) for which R_2 represents -ORa, Ra being as defined for the compound of formula (I), correspond to the formula (Id). They can be obtained from the compounds of formula (X) according to the following Scheme 2. The compounds of formula (Ic), obtained by a hydrogenolysis reaction on the compounds of formula (X), are subjected, for example, to an alkylation reaction with an alkylating agent of type Ra-X, in which Ra is as defined for the compound of formula (I) and X represents a leaving group (such as a halogen atom, for example), in the presence of a base, such as caesium carbonate (Cs_2CO_3), or also to a Mitsunobu reaction (Synthesis, 1981, 1) with an alcohol of type Ra-OH, Ra being as defined for the compound of formula (I), to give compounds of formula (Id).

The compounds of formula (X) and the compounds of formula (Ic) are compounds of formula (I) and can act as intermediate for other compounds of formula (I), such as the compounds of formula (Id).

Scheme 2




Alternatively, the compounds of formula (Id) can be obtained by following the procedure described in Scheme 3.

The compounds of formula (XII) are obtained by a nucleophilic aromatic substitution reaction involving a compound of formula (XI), in which R' is as defined above, and an alcohol of type Ra-OH, in which Ra is as defined for the compound of formula (I), in the presence of a base. The reduction of the nitro group of the compounds of formula (XII) results in the corresponding anilino derivatives (XIII). A reductive amination reaction with a compound of formula (III), in which PG is a protective group for amine functional groups, such as, for example, boc, results in the compounds of formula (XIV). The compounds of formula (XV) are obtained by reaction of a compound of formula (XIV) with potassium isocyanate (KNCO) in an acid medium. An intramolecular cyclization reaction in a basic medium makes it possible to obtain the compounds of formula (XVI). The protective group PG is cleaved by methods well known to a person skilled in the art to give the compounds of formula (XVII). An acylation reaction results in the compounds of formula (XVIII). Finally, the compounds of formula (Id) are obtained either by an alkylation reaction with a derivative of type (XIX), in which X represents a leaving group, such as a halogen atom, in the presence of a base, such as, for example,

caesium carbonate, or also by a Mitsunobu reaction with a benzyl alcohol of type (XX). In the compounds (XIX) and (XX), R_3 is as defined above.

Scheme 3




The compounds of formula (Ie) and (If), in which R_2 more particularly represents a group of type–CH_2-NHC(O)Rb, Rb being defined as in the compound of formula (I), can be prepared according to the following Scheme 4.

It is understood that, in Scheme 3, the R_2 group illustrated is of -O-Ra type and is

in the 6 position of the quinoazolinedione structure (see, for example, compound (XVIII)) but that it is also possible to have a second R_2 group, as defined in the general formula (I), in the 7 position of the same quinazolinedione group.

The reduction of the nitro group of the compounds of type (XXI), in which R' and PG' are as defined above, the PG' group advantageously being boc, results in the corresponding anilino derivatives (XXII) which, by a reductive amination reaction in which they react in an acid medium and advantageously in the presence of a reducing agent, such as sodium triacetoxyborohydride, with a compound of formula (III), in which PG represents a benzyloxycarbonyl protective group for amines, give compounds of formula (XXIII). An acylation reaction with an alkyl or aryl chloroformate, in which R" represents a (C_1-C_6) alkyl group or an aryl group which is substituted, results in the compounds of formula (XXIV). The quinazolinedione analogues of formula (XXV) can be obtained by a hydrolysis reaction in a basic medium and then by a coupling reaction with a compound of formula (VII), in which R_3 is as defined for the compound of formula (I), followed by an intramolecular cyclization reaction in a basic medium. The PG' group (preferably a boc) is subsequently cleaved in an acid medium to result in the compounds of formula (XXVI) which, by acylation, give compounds of formula (XXVII), in which Rb is as defined for the compound of formula (I). The PG protective group of (XXVII) is cleaved by a hydrogenolysis reaction to give the compounds of formula (Ie). Finally, the compounds of formula (If) are obtained by an acylation reaction on the compounds of formula (Ie).

Scheme 4



It is obvious that a person skilled in the art will be in a position to choose, in the light of his knowledge and the literature, other appropriate protective groups which make possible the introduction of all the groups described in the general formula (I).

When the compound of formula (I) comprises a bridged ring, it can be obtained without distinction by one of the synthetic routes described above.

The following procedures and examples describe the preparation of some

compounds in accordance with the invention. These procedures and examples are not limiting and serve only to illustrate the present invention.

In the procedures and examples below:

- the mass spectra are produced on a quadrupole spectrometer of Platform LCZ type (Waters) or of ZQ 4000 type (Waters) in positive electrospray ionization mode;
- the NMR (nuclear magnetic resonance) spectra are produced on a Fourier transform spectrometer (Bruker) at a temperature of 300°C (exchangeable protons not recorded);
- s = singlet,
- d = doublet,
- m = multiplet,
- br = broad signal
- t = triplet,
- q = quartet
- DMSO-d_6 = deuterated dimethyl sulphoxide,
- $CDCl_3$ = deuterated chloroform.

The mixtures of solvents are quantified in volumetric ratios.

The NMR spectra and mass spectra confirm the structures of the compounds obtained according to the examples below.

In the examples which follow, the following abbreviations are used:
ACN: acetonitrile
AcOEt: ethyl acetate
AcOH: acetic acid
DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene
DCM: dichloromethane
DCE: 1,2-dichloroethane
DIAD: diisopropyl azodicarboxylate
DIEA: diisopropylamine
DMF: N,N-dimethylformamide
EtOH: ethanol
HBTU: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
IBCF: isobutyl chloroformate
MeOH: methanol
$NaBH(OAc)_3$: sodium triacetoxyborohydride
AT: ambient temperature

min: minute

THF: tetrahydrofuran

NEt_3: triethylamine


TFA: trifluoroacetic acid

EXAMPLES

The following examples describe the preparation of some compounds in accordance with the invention. These examples are not limiting and serve only to illustrate the present invention. The numbers of the compounds in the examples refer to those given in the table below, in which the chemical structures and the physical properties of a few compounds in accordance with the invention are illustrated.


EXAMPLE 1: Compound No.°6

Preparation of {[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile



Stage 1.1:


1,1-Dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate



A mixture of 2 g of methyl 2-amino-5-(benzyloxy)benzoate, 3.1 g of 1,1-dimethylethyl 4-oxopiperidine-1-carboxylate and 3.29 g of $NaBH(OAc)_3$ in 10 ml of AcOH is irradiated under a microwave field (Biotage Initiator Sixty) at 110°C for 20 min. The same reaction is repeated with two other lots of 2 g of methyl 2-amino-5-(benzyloxy)benzoate. The three reaction media are combined. The combined product is taken up in AcOEt. The organic phase is washed with water, with a saturated NH_4Cl solution and with a saturated $NaHCO_3$ solution, dried over Na_2SO_4 and filtered, and the solvent is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (5/95, v/v) as far as (30/70, v/v), to give 10.2 g of the expected product.

Stage 1.2:

1,1-Dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl][(2-methylpropoxy)carbonyl]amino}piperidine-1-carboxylate




A mixture of 2 g of 1,1-dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate obtained in stage 1.1, 0.87 ml of DIEA, 1.78 ml of IBCF and 1 g of NaOH in 10 ml of DCE is irradiated under a microwave field at 80°C for 30 min. The same reaction is repeated with 4 other lots of 2 g of 1,1-dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate. The 5 reaction media are combined. The combined product is taken up in AcOEt and filtered, and the filtrate is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (10/90, v/v) as far as (50/50, v/v), to give 9.3 g of the expected product.

Stage 1.3:

Sodium salt of 5-(benzyloxy)-2-({1-[(1,1-dimethylethoxy)carbonyl]-piperidin-


4-yl}[(2-methylpropoxy)carbonyl]amino)benzoic acid



A mixture of 9.3 g of 1,1-dimethylethyl 4-{[4-(benzyloxy)-2-(methoxycarbonyl)phenyl][(2-methylpropoxy)carbonyl]amino}piperidine-1-carboxylate obtained in stage 1.2 and 34.4 ml of 2N NaOH in 57 ml of MeOH is heated at 100°C for 3h 00. The solution is evaporated under reduced pressure and DCM is added. Drying is carried out over Na_2SO_4, filtration is carried out and the solvent is evaporated under reduced pressure to give 8.7 g of the expected product.

Stage 1.4:

1,1-Dimethylethyl 4-[{4-(benzyloxy)-2-[(3,4-dimethoxybenzyl)carbamoyl]phenyl}(isobutoxycarbonyl)amino]piperidine-1-carboxylate




A mixture of 6 g of sodium salt of 5-(benzyloxy)-2-({1-[(1,1-dimethylethoxy)carbonyl]piperidin-4-yl}[(2-methylpropoxy)carbonyl]amino)benzoic acid obtained in stage 1.3 and 4.42 g of DIEA in 250 ml of DMF is stirred at AT for 15 min. 6.48 g of HBTU are added and the mixture is left stirring for 30 min. 2.48 g of veratrylamine are added and the reaction mixture is stirred for 48h 00. It is evaporated under reduced pressure, the residue is taken up in AcOEt, washed with a saturated

NH_4Cl solution and with a saturated $NaHCO_3$ solution, dried over Na_2SO_4 and filtered, and the solvent is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (20/80, v/v) as far as (60/40, v/v), to give 7.5 g of expected product.

Stage 1.5:


1,1-Dimethylethyl 4-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carboxylate



A mixture of 2.5 g of 1,1-dimethylethyl 4-[{4-(benzyloxy)-2-[(3,4-dimethoxybenzyl)carbamoyl]phenyl}(isobutoxycarbonyl)amino]piperidine-1-carboxylate obtained in stage 1.4 and 7.4 g of NaOH in 18.5 ml of DCE is irradiated under a microwave field at 110°C for 30 min. The same reaction is repeated with 2 other lots of 2.5 g of 1,1-dimethylethyl 4-[{4-(benzyloxy)-2-[(3,4-dimethoxybenzyl)carbamoyl]phenyl}-(isobutoxycarbonyl)amino]piperidine-1-carboxylate. The 3 reaction media are combined. The combined product is taken up in DCM, washed with water, dried over Na_2SO_4 and filtered, and the solvent is evaporated under reduced pressure to give 6.6 g of expected product.

Stage 1.6:


6-(Benzyloxy)-3-(3,4-dimethoxybenzyl)-1-(piperidin-4-yl)quinazoline-2,4(1H,3H)-dione



A mixture of 3.5 g of 1,1-dimethylethyl 4-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carboxylate obtained in stage 1.5 and 25 ml of TFA in 50 ml of DCM is stirred at AT for 2h 00. The mixture is neutralized with K_2CO_3. It is filtered and the filtrate is evaporated under reduced pressure. The residue is taken up in DCM and washed with a saturated $NaHCO_3$ solution and then with an 8% NaOH solution. The solution is dried over Na_2SO_4 and filtered, and the solvent is evaporated under reduced pressure to give 2.67 g of the expected product.

Stage 1.7:

4-[6-(Benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde




A mixture of 0.6 g of 6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-1-(piperidin-4-yl)quinazoline-2,4(1H,3H)-dione obtained in stage 1.7 and 0.113 g of ammonium formate in 5 ml of ACN is irradiated under a microwave field at 140°C for 1h 00. The mixture is filtered and the filtrate is evaporated under reduced pressure to give 0.62 g of the expected product.

Stage 1.8: Compound No. 5:

4-[3-(3,4-Dimethoxybenzyl)-6-hydroxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-


yl]piperidine-1-carbaldehyde



A mixture of 0.618 g of 4-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde obtained in stage 1.7, 0.44 g of ammonium formate and 0.124 g of Pd/C (10%) in 10 ml of EtOH purged beforehand with nitrogen is irradiated under a microwave field at 80°C for 2h 00. The mixture is filtered and the filtrate is evaporated under reduced pressure to give 0.513 g of the expected product.

<u>Stage 1.9</u>: Compound No. 6


{[3-(3,4-Dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile



0.17 g of 4-[3-(3,4-dimethoxybenzyl)-6-hydroxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde obtained in stage 1.8 and 0.25 g of Cs_2CO_3 in 3 ml of DMF are stirred for 15 min at AT. 0.056 g of bromoacetonitrile is added and the reaction mixture is subsequently irradiated under a microwave field at 100°C for 15 min. It is filtered and evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an MeOH/DCM mixture, (1/99, v/v) as far as (4/96, v/v), to give 0.112 g of the expected product.


EXAMPLE 2: Compound No. 3

Preparation of {[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile



Stage 2.1:


1-(1-Acetylpiperidin-4-yl)-6-(benzyloxy)-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1*H*,3*H*)-dione



0.14 g of acetyl chloride is added to a mixture of 0.6 g of 6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-1-(piperidin-4-yl)quinazoline-2,4(1H,3H)-dione obtained according to stage 1.6 and 0.24 g of NEt_3 in 10 ml of DCM cooled to 0°C. The mixture is stirred at AT overnight. It is washed twice with a saturated NH_4Cl solution and filtered, and then the filtrate is evaporated under reduced pressure to give 0.64 g of the expected product.

Stage 2.2: Compound No. 2


1-(1-Acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline-2,4(1H,3H)-dione



A mixture of 0.64 g of 1-(1-acetylpiperidin-4-yl)-6-(benzyloxy)-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1*H*,3*H*)-dione obtained in stage 2.1, 0.44 g of ammonium formate and 0.125 g of Pd/C (10%) in 10 ml of EtOH purged beforehand with nitrogen is irradiated under a microwave field at 80°C for 2h 00. The mixture is filtered and the filtrate is evaporated under reduced pressure to give 0.48 g of the expected product.

Stage 2.3: Compound No. 3


{[1-(1-Acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile



0.12 g of 1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline-2,4(1H,3H)-dione obtained in stage 2.2 and 0.172 g of Cs_2CO_3 in 3 ml of DMF are stirred for 15 min at AT. 0.038 g of bromoacetonitrile is added and the reaction mixture is subsequently irradiated under a microwave field at 100°C for 15 min. It is filtered and the filtrate is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an MeOH/DCM mixture, (1/99, v/v) as far as (4/96, v/v), to give 0.094 g of the expected product.


EXAMPLE 3: Compound No. 34

Synthesis of 4-[3-(4-chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl]piperidine-1-carbaldehyde



Stage 3.1:


Methyl 5-(2,2-difluoroethoxy)-2-nitrobenzoate



8.53 g of 2,2-difluoroethanol are added to a solution of 17.31 g of methyl 5-fluoro-2-nitrobenzoate, 9.64 g of NEt_3 and 32.71 g of 2,8,9-triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo[3.3.3]undecane in 250 ml of anhydrous THF. The mixture is stirred at AT for 30 min. The solvent is evaporated under reduced pressure. Water is added and extraction is carried out with AcOEt. The extract is washed with a 1N aqueous HCl solution, with water and then with a saturated NaCl solution. It is dried over $MgSO_4$ and filtered, and the solvent is evaporated under reduced pressure to give 21 g of the expected product.

Stage 3.2:

Methyl 2-amino-5-(2,2-difluoroethoxy)benzoate




21 g of methyl 5-(2,2-difluoroethoxy)-2-nitrobenzoate obtained in stage 3.1 and 1 g of Pd/C (10%) in a mixture of 300 ml of AcOEt, 50 ml of EtOH and 5 ml of AcOH are stirred at AT under a hydrogen atmosphere for 24h 00.

The mixture is filtered and evaporated under reduced pressure to give 18.6 g of the expected product.

Stage 3.3:


1,1-Dimethylethyl 4-{[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate



A mixture of 4 g of methyl 2-amino-5-(2,2-difluoroethoxy)benzoate and 6.88 g of 1,1-dimethylethyl 4-oxopiperidine-1-carboxylate obtained in stage 3.2 in 15 ml of AcOH is heated at 90°C for 10 min. It is allowed to cool to AT and 7.3 g of $NaBH(OAc)_3$ are added. The mixture is left stirring at AT for 12h 00. It is extracted with AcOEt and the extract is washed with a saturated K_2CO_3 solution and then with water. It is dried over $MgSO_4$, filtered and evaporated under reduced pressure to give 6.63 g of the expected product.

Stage 3.4:

1,1-Dimethylethyl 4-{carbamoyl[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)-phenyl]amino}piperidine-1-carboxylate




1.95 g of potassium isocyanate in solution of 4 ml of water are added to a solution of 6.63 g of 1,1-dimethylethyl 4-{[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)phenyl] amino}piperidine-1-carboxylate obtained in stage 3.3 in 40 ml of AcOH. The mixture is

stirred at AT for 12h 00. It is extracted with AcOEt and the extract is washed with a saturated K_2CO_3 solution and then with water. It is dried over $MgSO_4$, filtered and evaporated under reduced pressure to give 6.95 g of the expected product.

Stage 3.5:


1,1-Dimethylethyl 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl]piperidine-1-carboxylate



2.5 g of 1,1-dimethylethyl 4-{carbamoyl[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate obtained in stage 3.4 in solution in a mixture of 10 ml of dioxane and 5 ml of a 1N aqueous NaOH solution are irradiated under a microwave field at 130°C for 30 min. Extraction is carried out with AcOEt and the extract is neutralized with a 1N aqueous HCl solution, washed with water, dried over $MgSO_4$, filtered and evaporated under reduced pressure. The residue obtained is triturated in an AcOEt/pentane mixture to give the expected product. The same reaction is reproduced with 2 other lots of 2.5 g of 1,1-dimethylethyl 4-{carbamoyl[4-(2,2-difluoroethoxy)-2-(methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate obtained in stage 3.4 to give, in total, 5.63 g of expected product.

Stage 3.6:


6-(2,2-Difluoroethoxy)-1-(piperidin-4-yl)quinazoline-2,4(1*H*,3*H*)-dione



A solution of 5.63 g of 1,1-dimethylethyl 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl]piperidine-1-carboxylate obtained in stage 3.5 in 70 ml of formic acid is stirred at AT for 2h 00. The solvent is evaporated under reduced pressure to give 6.13 g of the expected product in the form of the formic acid salt.

Stage 3.7:


4-[6-(2,2-Difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl]piperidine-1-carbaldehyde



A mixture of 6.13 g of 6-(2,2-difluoroethoxy)-1-(piperidin-4-yl)quinazoline-2,4(1*H*,3*H*)-dione obtained in stage 3.6 and 3.12 g of ammonium formate in 28 ml of ACN and 28 ml of dioxane is irradiated under a microwave field at 140°C for 1h 00. The reaction mixture is run into water. The mixture is filtered and the precipitate is washed with water and then with ether to give 4.47 g of the expected product.

Stage 3.8: Compound No. 34


4-[3-(4-Chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl]piperidine-1-carbaldehyde



A mixture of 0.15 g of 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl]piperidine-1-carbaldehyde obtained in stage 3.7, 0.096 g of 1-(bromomethyl)-4-chlorobenzene and 0.3 g of Cs_2CO_3 in 3 ml of DMF is stirred at AT for 1h 00. AcOEt is added and washing is carried out with water and then with a saturated NaCl solution. The organic phase is dried over $MgSO_4$, filtered and evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with AcOEt, to give 0.116 g of the expected product.

EXAMPLE 4: Compound No. 49


Synthesis of 4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl}piperidine-1-carbaldehyde



0.172 g of DIAD is added to a solution of 0.15 g of 4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl]piperidine-1-carbaldehyde obtained in stage 3.7, 0.142 g of [4-(cyclopentyloxy)-3-methoxyphenyl]methanol and 0.223 g of PPh_3 in 3 ml of anhydrous THF. The mixture is stirred at AT for 12h 00 and then at 60°C for 1h 00. It is evaporated under reduced pressure and the residue is purified on silica gel, elution being carried out with AcOEt, to give 0.083 g of the expected product.


EXAMPLE 5: Compound No. 20

Synthesis of *N*-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide



Stage 5.1:


Methyl 2-amino-5-({[(1,1-dimethylethoxy)carbonyl]amino}methyl)benzoate



A mixture of 0.273 g of methyl 5-{[(tert-butoxycarbonyl)amino]methyl}-2-nitrobenzoate, 0.166 g of ammonium formate and 0.094 g of Pd/C (10%) in 10 ml of EtOH purged beforehand with nitrogen is irradiated under a microwave field at 120°C for 5 min. The mixture is filtered and the filtrate is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (5/95, v/v) as far as (30/70, v/v), to give 0.2 g of the expected product.

Stage 5.2:


Benzyl 4-{[4-({[(1,1-dimethylethoxy)carbonyl]amino}methyl)-2-(methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate



A solution of 1.66 g of benzyl 4-oxopiperidine-1-carboxylate and 1 g of methyl 2-amino-5-({[(1,1-dimethylethoxy)carbonyl]amino}methyl)benzoate obtained in stage 5.1 in 20 ml of DCM is added dropwise at AT to a suspension of 2.04 g of $NaBH(OAc)_3$ in a mixture of 20 ml of DCM and 0.41 ml of AcOH. The mixture is stirred at AT for 15h 00 and then a further 2.04 g of $NaBH(OAc)_3$ are added. After stirring for 6h 00, 1.66 g of benzyl 4-oxopiperidine-1-carboxylate are added and the mixture is stirred at AT for 48h 00. A saturated $NaHCO_3$ solution is added and extraction is carried out with DCM. The organic phase is washed with a saturated $NaHCO_3$ solution and twice with a saturated NH_4Cl solution. It is dried over Na_2SO_4 and filtered, and the filtrate is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (5/95, v/v) as far as (40/60, v/v), to give 1.6 g of the expected product.

Stage 5.3:


Benzyl 4-{[4-({[(1,1-dimethylethoxy)carbonyl]amino}methyl)-2-(methoxycarbonyl)phenyl](ethoxycarbonyl)amino}piperidine-1-carboxylate



2.08 g of DIEA and then 1.745 g of ethyl chloroformate are added to a solution of 1.6 g of benzyl 4-{[4-({[(1,1-dimethylethoxy)carbonyl]amino}methyl)-2-(methoxycarbonyl)phenyl]amino}piperidine-1-carboxylate obtained in stage 5.2 in 11 ml of DCM. The mixture is stirred at AT for 4 days. It is evaporated under reduced pressure. The residue is taken up in 10 ml of pyridine (10 ml) and 0.7 g of ethyl chloroformate is added. The mixture is stirred at AT for 4h 00. It is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/heptane mixture, (10/90, v/v) as far as (30/70, v/v), to give 0.875 g of the expected product.

Stage 5.4:


Benzyl 4-[3-(3,4-dimethoxybenzyl)-6-({[(1,1-dimethylethoxy)carbonyl]amino}-methyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl]piperidine-1-carboxylate



A mixture of 0.165 g of benzyl 4-{[4-({[(1,1-dimethylethoxy) carbonyl]amino}-methyl)-2-(methoxycarbonyl)phenyl](ethoxycarbonyl)amino}piperidine-1-carboxylate obtained in stage 5.3 and 0.028 g of LiOH in 5 ml of THF/H_2O (70/30) is stirred at AT for 15h 00. The mixture is subsequently irradiated under a microwave field at 100°C for 1h 00. It is filtered and the filtrate is evaporated under reduced pressure. The residue is taken up in 5 ml of DMF. 0.108 g of DIEA is added and the mixture is stirred at AT for 10 min. 0.159 g of HBTU is added and the mixture is stirred at AT for 30 min. 0.061 g of veratrylamine is subsequently added and the mixture is stirred at AT for 1h 00. 0.5 ml of DBU is added and the mixture is stirred at AT for 48h 00. It is evaporated under reduced pressure and the residue is taken up in AcOEt. The solution is washed 3 times with a saturated NH_4Cl solution and twice with water. It is dried over Na_2SO_4 and filtered, and the filtrate is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an AcOEt/DCM mixture, (10/90, v/v) as far as (20/80, v/v), to give 0.104 g of the expected product.

Stage 5.5:


Benzyl 4-[6-(aminomethyl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydro-quinazolin-1(2*H*)-yl]piperidine-1-carboxylate



A solution of 0.102 g of benzyl 4-[3-(3,4-dimethoxybenzyl)-6-({[(1,1-dimethylethoxy)carbonyl]amino}methyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl]piperidine-1-carboxylate obtained in stage 5.4 and 0.5 ml of TFA in 9.5 ml of DCM is stirred at AT for 2h 00. A saturated $NaHCO_3$ solution is added. The organic phase is dried over Na_2SO_4 and filtered, and the filtrate is evaporated under reduced pressure to give 0.09 g of the expected product.

Stage 5.6:


Benzyl 4-{6-[(acetylamino)methyl]-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl}piperidine-1-carboxylate



0.049 g of acetic anhydride is added to a solution of 0.09 g of benzyl 4-[6-(aminomethyl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl]piperidine-1-carboxylate obtained in stage 5.5 and 0.09 ml of NEt_3 in 3 ml of DCM and the mixture is stirred at AT for 1h 00. DCM is added and the solution is washed with a saturated NH_4Cl solution, then with a 1N HCl solution, then with a 2N NaOH solution and then with water. The organic phase is dried over Na_2SO_4 and filtered, and the filtrate is evaporated under reduced pressure to give 0.104 g of the expected product.

Stage 5.7:


***N*-{[3-(3,4-Dimethoxybenzyl)-2,4-dioxo-1-(piperidin-4-yl)-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide**



A mixture of 0.1 g of benzyl 4-{6-[(acetylamino)methyl]-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2*H*)-yl}piperidine-1-carboxylate obtained in stage 5.6, 0.016 g of ammonium formate and 0.018 g of Pd/C (10%) in 2 ml of EtOH purged beforehand with nitrogen is irradiated under a microwave field at 80°C for 30 min. The mixture is filtered and the filtrate is evaporated under reduced pressure to give 0.077 g of the expected product.







Stage 5.8: Compound No. 20







***N*-{[3-(3,4-Dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide**














A mixture of 0.070 g of *N*-{[3-(3,4-dimethoxybenzyl)-2,4-dioxo-1-(piperidin-4-yl)-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide obtained in stage 5.7 and 0.028 g of ammonium formate in 2 ml of ACN is irradiated under a microwave field at 140°C for 1h 00. The mixture is filtered and the filtrate is evaporated under reduced pressure. The residue is chromatographed on silica gel, elution being carried out with an MeOH/DCM mixture, (0.5/99.5, v/v) as far as (7/93, v/v), to give 0.035 g of the expected product.





The chemical structures and the physical properties of compounds corresponding to the general formula (I) according to the invention, and also of some of their intermediates (in particular compounds 32, 55, 120 and 257), are illustrated in the following table.





COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
1		2-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}propanenitrile	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.71(d, 3H) 1.79(brdd, 2H) 2.41(dq, 1H) 2.53(dq, 1H) 2.80(td, 1H) 3.25(t, 1H) 3.70(s, 3H) 3.71(s, 3H) 3.80(d, 1H) 4.31(d, 1H) 4.77(brs, 1H) 5.03(s, 2H) 5.60(q, 1H) 6.83(dd, 1H) 6.85 (d, 1H) 6.98(s, 1H) 7.51(dd, 1H) 7.74(d, 1H) 7.84(d, 1H) 8.03(s, 1H)
2		1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-hydroxyquinazoline-2,4(1H,3H)-dione	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.69(d, 1H) 1.74(d, 1H) 2.05(s, 3H) 2.42(dq, 1H) 2.57(dq, 1H) 2.70(t, 1H) 3.24(t, 1H) 3.70(br s, 3H) 3.71(s, 3H) 3.92(d, 1H) 4.51(d, 1H) 4.69(brs, 1H) 5.02(s, 2H) 6.81(dd, 1H) 6.86(d, 1H) 6.97(d, 1H) 7.21(dd, 1H) 7.44(d, 1H) 7.65(d, 1H) 9.88(brs, 1H)
3		{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.71(d, 1H) 1.76(d, 1H) 2.04(s, 3H) 2.41(dq, 1H) 2.56(dq, 1H) 2.70(t, 1H) 3.24(t, 1H) 3.70(s, 3H) 3.71(s, 3H) 3.92(d, 1H) 4.51(d, 1H) 4.73(brs,1 H) 5.04(s, 2H) 5.29(s, 2H) 6.82(dd, 1H) 6.85(d, 1H) 6.98(d, 1H) 7.50(dd, 1H) 7.70(d, 1H) 7.83(d, 1H)
4		2-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}propanenitrile	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.71(d, 3H) 1.72(d, 2H) 1.77(d, 1H) 2.04(s, 3H) 2.41(qd, 1H) 2.56(dq, 1H) 2.70(d, 1H) 3.24(t, 1H) 3.70(s, 3H) 3.71(s, 3H) 3.92(d, 1H) 4.51(d, 1H) 4.73(brs, 1H) 5.03(s, 2H) 5.60(q, 1H) 6.83(d, 1H) 6.85(m, 1H) 6.98(d, 1H) 7.51(dd, 1H) 7.74(d, 1H) 7.83(d, 1H)
5		4-[3-(3,4-dimethoxybenzyl)-6-hydroxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.75(d, 1H) 1.78(d, 1H) 2.41(qd, 1H) 2.53(qd, 1H) 2.79(td, 1H) 3.25(td, 1H) 3.70(s, 3H) 3.71(s, 3H) 3.80(d, 1H) 4.31(d, 1H)4.72 (brs, 1H) 5.02(s, 2H) 6.82(dd, 1H) 6.86(d, 1H) 6.97(d, 1H) 7.21(dd, 1H) 7.44(d, 1H) 7.66(d, 1H) 8.03(s, 1H) 9.85(brs, 1H)
6		{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.78(d, 1H) 1.81(d, 1H) 2.42(qd, 1H) 2.54(dt, 1H) 2.81(td, 4H) 3.26(dt, 1H) 3.71(s, 3H) 3.72(s, 3H) 3.81(d, 1H) 4.32(d, 1H) 4.77(brs, 1H) 5.05(s, 2H) 5.30(s, 2H) 6.84(dd, 1H) 6.87(d, 1H) 6.99(d, 1H) 7.51(dd, 1H) 7.71(d, 1H) 7.85(d, 1H) 8.04(s, 1H)







COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
7		2-{[3-(3,4-dimethoxybenzyl)-2,4-dioxo-1-(piperidin-4-yl)-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}propanenitrile	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm1.69(d, 3H) 1.75(d, 2H) 2.65(td, 2H) 2.87(t, 2H) 3.21(d, 2H) 3.69(s, 3H) 3.70(s, 3H) 4.68(brs, 1H) 5.04(s, 2H) 5.59(q, 1H) 6.84(m, 2H) 6.98(d, 1H) 7.50(dd, 1H) 7.73(d, 1H) 7.80(d, 1H)
8		{[3-(3,4-dimethoxybenzyl)-2,4-dioxo-1-(piperidin-4-yl)-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}acetonitrile	^{1}H NMR (600 MHz, DMSO-d_6) δ ppm 1.77(d, 2H) 2.67(dt, 2H) 2.89(t, 2H) 3.23(d, 2H) 3.69(s, 3H) 3.70(s, 3H) 4.69(brs, 1H) 5.05(s, 2H) 5.28(s, 2H) 6.84(m, 2H) 6.99(s, 1H) 7.49(dd, 1H) 7.70(d, 1H) 7.80(d, 1H)
9		2-{[3-(3,4-dimethoxybenzyl)-1-(1-methylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}propanenitrile	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.59(d, 2H) 1.66(d, 3H) 2.04(t, 2H) 2.16(s, 3H) 2.62(dt, 2H) 2.82(d, 2H) 3.66(s, 3H) 3.67(s, 3H) 4.43(brs, 1H) 5.01(s, 2H) 5.54(q, 1H) 6.79(m, 1H) 6.82(d, 1H) 6.95(d, 1H) 7.45(dd, 1H) 7.68(d, 1H) 7.70(d, 1H)
10		3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-piperidin-4-ylquinazoline-2,4(1H,3H)-dione	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.85(d, 2H) 2.78(td, 2H) 3.04(t, 2H) 3.33(d, 2H) 3.71(s, 6H) 4.61-4.82(m, 4H) 5.04(brt, 1H) 5.05(s, 2H) 6.86(m, 2H) 6.99(s, 1H) 7.49(dd, 1H) 7.68(d, 1H) 7.76(d, 1H) 8.05(brs, 1H)
11		4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.76(d, 1H) 1.80(d, 1H) 2.41(qd, 1H) 2.53(qd, 1H) 2.80(td, 1H) 3.25(dt, 1H) 3.70(s, 6H) 3.80(d, 1H) 4.31(d, 1H) 4.61-4.83(m, 5H) 5.02(m, 1H) 5.03(s, 2H) 6.83(dd, 1H) 6.85(d, 1H) 6.97(d, 1H) 7.47(dd, 1H) 7.67(d, 1H) 7.77(d, 1H) 8.03(s, 1H)
12		1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.70(d, 1H) 1.76(d, 1H) 2.04(s, 3H) 2.41(dq, 1H) 2.56(dq, 1H) 2.70(t, 1H) 3.25(t, 1H) 3.70(s, 3H) 3.71(s, 3H) 3.92(d, 1H) 4.51(d, 1H) 4.61-4.83(m, 5H) 5.02(m, 1H) 5.03(s, 2H) 6.82(dd, 1H) 6.85(m, 1H) 6.97(d, 1H) 7.47(dd, 1H) 7.67(d, 1H) 7.77(d, 1H)






COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
13		4-[3-(3,4-dimethoxybenzyl)-2,4-dioxo-6-(2,2,2-trifluoroethoxy)-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (600 MHz, DMSO-d_6) δ ppm 1.75(d, 1H) 1.79(d, 1H) 2.40(dq, 1H)) 2.52(dq, 1H) 2.79(td, 1H) 3.25(td, 1H) 3.69(s, 6H) 3.79(d, 1H) 4.30(d, 1H) 4.75(brs, 1H) 4.88(q, 2H) 5.02(s, 2H) 6.82(d, 1H) 6.85(d, 1H) 6.97(s, 1H) 7.49(dd, 1H) 7.66(d, 1H) 7.79(d, 1H) 8.02(s, 1H)
14		1-(1-acetylpiperidin-4-yl)-6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.70(d, 1H) 1.74(d, 1H) 2.04(s, 3H) 2.41(qd, 1H) 2.56(qd, 1H) 2.70(t, 1H) 3.24(t, 1H) 3.70(s, 3H) 3.70(s, 3H) 3.91(d, 1H) 4.43(td, 2H) 4.50(d, 1H) 4.73(brs,1H) 5.03 (s, 2H) 6.41(tt, 1H) 6.82(dd, 1H) 6.85(d, 1H) 6.97(d, 1H) 7.46(dd, 1H) 7.60(d, 1H) 7.79(d, 1H)
15		6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-1-(piperidin-4-yl)quinazoline-2,4(1H,3H)-dione	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.83(d, 2H) 2.75(td, 2H) 3.00(t, 2H) 3.30(d, 2H) 3.71(s, 6H) 4.44(td, 2H) 4.75(b. s, 1H) 5.06(s, 2H) 6.42(tt, 1H) 6.83-6.89(m, 2H) 7.00(s, 1H) 7.48(dd, 1H) 7.62(d, 1H) 7.78(d, 1H)
16		4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.76(d, 1H) 1.80(d, 1H) 2.41(qd, 1H) 2.53(qd, 1H) 2.81(td, 1H) 3.26(td, 1H) 3.71(s, 6H) 3.80(d, 1H) 4.31(d, 1H) 4.44(td, 2H) 4.77(brs, 1H) 5.04(s, 2H) 6.42(tt, 1H) 6.83(m, 1H) 6.86(d, 1H) 6.86(d, 1H) 6.98(d, 1H) 7.47(dd, 1H) 7.61(d, 1H) 7.80(d, 1H) 8.03(s, 1H)
17		1,1-dimethylethyl 4-[3-(3,4-dimethoxybenzyl)-6-hydroxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carboxylate	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.43(s, 9H) 1.67(d, 2H) 2.48(m, 2H) 2.92(brs, 2H) 3.70(s, 3 H) 3.71(s, 3H) 4.05(br s, 2H) 4.61(brs, 1H) 5.02(s, 2H) 6.80(dd, 1H) 6.86(d, 1H) 6.97(d, 1H) 7.20(dd, 1H) 7.43(d, 1H) 7.62(d, 1H) 9.95(brs, 1H)
18		3-(3,4-dimethoxybenzyl)-6-hydroxy-1-(1-methylpiperidin-4-yl)quinazoline-2,4(1H,3H)-dione	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.60(d, 2H) 2.06(td, 2H) 2.19(s, 3H) 2.65(qd, 2H) 2.85(d, 2H) 3.70(s, 3 H) 3.71(s, 3H) 4.43(br.s, 1H) 5.02(s, 2H) 6.81(m, 1H) 6.85(d, 1H) 6.98(d, 1H) 7.19(dd, 1H) 7.41(d, 1H) 7.55(d, 1H) 9.82(s, 1H)






COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
19		3-(3,4-dimethoxybenzyl)-6-hydroxy-1-(piperidin-4-yl)quinazoline-2,4(1H,3H)dione hydrochloride	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.86(d, 2H) 2.83(m, 2H) 3.12(t, 2H) 3.37(m, 2H) 3.70(s, 6H) 4.76(brs, 1H) 5.03(s, 2H) 6.83(dd, 1H) 6.85(d, 1H) 6.98(d, 1H) 7.21(dd, 1H) 7.44(d, 1H) 7.70(d, 1H) 8.70(brs, 2H) 9.91(s, 1H)
20		N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide	^{1}H NMR (500 MHz, DMSO-d_6) δ pm1.75(d, 1H) 1.78(d, 1H) 1.86(s, 3H) 2.40(qd, 1H) 2.53(qd, 1H) 2.79(t, 1H) 3.25(t, 1H) 3.69(s, 3H) 3.70(s, 3H) 3.80(d, 1H) 4.29(d, 2H) 4.31(d., 1H) 4.77(brs, 1H) 5.02(s, 2H) 6.80(dd, 1H) 6.85(d, 1H) 6.96(d, 1H) 7.65(dd, 1H) 7.76(d, 1H) 7.96(d, 1H) 8.02(s, 1H) 8.46(t, 1H)
21		6-(aminomethyl)-3-(3,4-dimethoxybenzyl)-1-(piperidin-4-yl)quinazoline-2,4(1H,3H)-dione hydrochloride	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.89(d, 2H) 2.83-2.92(m, 2H) 3.16(brs, 2H) 3.38-3.42(m, 2H) 3.71(s, 6H) 4.13(brs, 2H) 4.82-4.97(m, 1H) 5.07(s, 2H) 6.83-6.88(m, 2H) 7.00(s, 1H) 7.91-7.99(m, 2H) 8.24(s, 1H) 8.42(br s, 3H) 9.16(brs, 1H)
22		1-(1-acetylpiperidin-4-yl)-6-(aminomethyl)-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione hydrochloride	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.67-1.79(m, 2H) 2.05(s, 3H) 2.36-2.47(m, 1H) 2.51-2.61(m, 1H) 2.73(t, 1H) 3.27(t, 1H) 3.71(s, 6H) 3.93(d, 1H) 4.11-4.15(m, 2H) 4.52(d, 1H) 4.78(brs, 1H) 5.05(s, 2H) 6.82(d, 1H) 6.86(d, 1H) 6.98(s, 1H) 7.87(s, 2H) 8.24(s, 1H) 8.32(brs, 3H)
23		N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}formamide	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.73-1.83(m, 2H) 2.36-2.45(m., 1H) 2.48-2.57(m, 1H) 2.77-2.84(m, 1H) 3.23-3.29(m, 1H) 3.70(s, 1H) 3.71(s, 3H) 3.81(d, 1H) 4.31(d, 1H) 4.37(d, 2H) 4.77(brs, 1H) 5.04(s, 2H) 6.82(dd, 1H) 6.86(d, 1H) 6.98(d, 1H) 7.67(dd, 1H) 7.78(d, 1H) 7.99(d, 1H) 8.03(s, 1H) 8.16(s, 1H) 8.62(t, 1H)






COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
24		N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}formamide	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.67-1.78(m, 2H) 2.05(s, 3H) 2.35-2.48(m, 1H) 2.53-2.62(m, 1H) 2.72(t, 1H) 3.25(t, 1H) 3.70(s, 3H) 3.71(s, 3H) 3.93(d, 1H) 4.37(d, 2H) 4.52(d, 1H) 4.75(brs, 1H) 5.04(s, 2H) 6.82(dd, 1H) 6.86(d, 1H) 6.98(d, 1H) 7.67(dd,1 H) 7.78(d,1 H) 7.99(d, 1H) 8.16(s, 1H) 8.63(t, 1H)
25		N-{[1-(1-acetylpiperidin-4-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.63-1.81(m, 2H) 1.87(s, 3H) 2.05(s, 3H) 2.32-2.42(m, 1H) 2.54-2.63(m, 1H) 2.71(dt, 1H) 3.25(dt, 1H) 3.70(s, 3H) 3.71(s, 3H) 3.93(d, 1H) 4.30(d, 2H) 4.52(d, 1H) 4.76(brs, 1H) 5.04(s, 2H) 6.81(dd 1H) 6.86(d, 1H) 6.97(d, 1H) 7.65(dd, 1H) 7.76(d, 1H) 7.97(d, 1H) 8.47(t, 1H)
26	 HCl	6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-1-(piperidin-3-yl)quinazoline-2,4(1H,3H)-dione hydrochloride	^{1}H NMR (600 MHz, DMSO-d_6) δ ppm 1.86-1.97(m, 3H) 2.54-2.62(m, 1H) 2.85-2.92(m, 1H) 3.31-3.35(m, 1H) 3.37-3.42(m, 1H) 3.71(s, 3H) 3.72(s, 3H) 3.73-3.78(m,1H) 3.76(t, 1H) 4.45(td, 2H) 4.87(br s, 1H) 5.05(s, 2H) 6.41(tt, 1H) 6.83-6.88(m, 2H) 6.99(s, 1H) 7.52(dd, 1H) 7.63(d, 1H) 7.72(d, 1H) 8.95(brs, 1H)
27	 HCl	6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-1-(pyrrolidin-3-yl)quinazoline-2,4(1H,3H)-dione hydrochloride	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 2.25-2.32(m, 1H) 2.42-2.48(m, 1H) 3.11-3.19(m, 1H) 3.38-3.45(m, 1H) 3.58-3.64(m, 1H) 3.65-3.72(m, 1H) 3.73(s, 3H) 3.71(s, 3H) 4.45(td, 2H) 5.05-5.12(m, 2H) 5.47-5.54(m, 1H) 6.42(tt, 1H) 6.82-6.88(m, 2H) 7.01(s, 1H) 7.55(dd, 1H) 7.62(d, 1H) 7.71(d, 1H) 8.87(brs, 1H)





COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
28		3-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (600 MHz, DMSO-d_6) mixture of two isomers δ ppm 1.52-1.62(m, 0.5H) 1.64-1.73(m, 0.5H) 1.75-1.84(m, 1H) 1.84-1.90(m, 1H) 2.54-2.67(m, 1.5H) 3.05(t, 0.5H) 3.59(t, 0.5H) 3.70(s, 3.5H) 3.70(s, 3H) 3.77(dd, 0.5H) 4.06(t, 0.5H) 4.17-4.27(m, 1H) 4.31(brs, 0.5H) 4.42(td, 2H) 4.44(brs, 0.5H) 5.04(s, 2H) 6.38(tt, 1H) 6.80-6.84(m, 1H) 6.84-6.88(m, 1H) 6.98(brs, 1H) 7.43(td, 1H) 7.60(brs, 1H) 7.62(d, 0.5H) 7.79(d, 0.5H) 7.99(s, 0.5H) 8.09(s, 0.5H)
29		1-(1-acetylpiperidin-3-yl)-6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione	^{1}H NMR (500 MHz, DMSO-d_6) mixture of two isomers δ ppm 1.55-1.65(m, 0.5H) 1.67-1.89(m, 2.5H) 1.99(s, 1.5H) 2.06(s, 1.5H) 2.52-2.65(m, 1H) 3.06(t, 0.5H) 3.30-3.37(m, 0.5H) 3.52(t, 0.5H) 3.70(s, 3H) 3.71(s, 3H) 3.52(t, 0.5H) 3.84(d, 0.5H) 3.91(d, 0.5H) 4.09(t, 0.5H) 4.28(brs, 0.5H) 4.39-4.48(m, 3H) 4.49(brs, 0.5H) 5.05(d, 2H) 6.41(tt, 1H) 6.81-6.89(m, 2H) 6.99(d, 1H) 7.44-7.48(m, 1H) 7.59-7.62(m, 1H) 7.64(d, 0.5H) 7.82(d, 0.5H)
30		3-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]pyrrolidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) mixture of two isomers δ ppm 2.18-2.27(m, 1H) 2.36-2.46(m, 1H) 3.41-3.48(m, 0.5H) 3.53-3.60(m, 0.5H) 3.63-3.73(m, 1.5H) 3.85-3.95(m, 1.5H) 4.43(td, 2H) 5.06(s, 2H) 5.38-5.45(m, 0.5H) 5.46-5.54(m, 0.5H) 6.41(tt, 1H) 6.82-6.88(m, 2H) 7.00(s, 1H) 7.46 - 7.51(m, 1H) 7.61(d, 1H) 7.66(d, 0.5H) 7.72(d, 0.5H) 8.16(s, 0.5H) 8.20(s, 0.5H)
31		1-(1-acetylpyrrolidin-3-yl)-6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione	^{1}H NMR (500 MHz, DMSO-d_6) mixture of two isomers δ ppm1.98(s, 1.5H) 2.04(s, 1.5H) 2.17-2.25(m, 0.5H) 2.27-2.35(m, 0.5H) 2.57-2.66(m, 1H) 3.40-3.45(m, 0.5H) 3 56-3.61(m, 0.5H) 3.70-3.78(m, 7.5H) 3.82-3.95(m, 1.5H) 4.48(td, 2H) 5.10(d, 2H) 5.45-5.58(m, 1H) 6.46(tt, 1H) 6.87-6.92(m, 2H) 7.05(dd, 1H) 7.53(td, 1H) 7.66(t, 1H) 7.72 (dd, 1H)

COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
32		4-[6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (600 MHz, DMSO-d_6) δ ppm 1.72-1.82(m, 2H) 2.35-2.44(m, 1H) 2.47-2.55(m, 1H) 2.79(td, 1H) 3.25(td, 1H) 3.80(d, 1H) 4.32(d, 1H) 4.42(td, 2H) 4.71(brs, 1H) 6.40(tt, 1H) 7.43(dd, 1H) 7.55(d, 1H) 7.74(d, 1H) 8.03(s, 1H)
33		4-[3-(3,4-dichlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.80(dd, 2H) 2.32-2.43(m, 1H) 2.44-2.52(m, 1H) 2.80(td, 1H) 3.26(dt, 1H) 3.80(brd, 1H) 4.31(br d, 1H) 4.44(td, 2H) 4.78(brs, 1H) 5.09(s, 2H) 6.41(tt, 1H) 7.30(dd, 1H) 7.49(dd, 1H) 7.58(d, 1H) 7.60(d, 1H) 7.62(d, 1H) 7.81(d, 1H) 8.03(s, 1H)
34		4-[3-(4-chlorobenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d6) δ ppm 1.72-1.83(m, 2H) 2.32-2.44(m, 1H) 2.45-2.53(m, 1H) 2.80(dt, 1H) 3.25-3.30(dt, 1H) 3.80 (d, 1 H) 4.30 (d,1 H) 4.44 (td, 2H) 4.78(brs, 1H) 5.09(s, 2H) 6.42 (tt, 1H) 7.32-7.40(m, 4H) 7.48(dd, 1H) 7.61(d, 1H) 7.81(d, 1H) 8.03(s, 1H)
35		Methyl 4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]methyl}benzoate	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.78(dd, 1H) 2.33-2.42(m, 1H) 2.44-2.52(m, 1H) 2.80(dt, 1H) 3.26(dt, 1H) 3.79(brd, 1H) 3.84(s, 3H) 4.30(brd, 1H) 4.45(td, 2H) 4.79(brs, 1H) 5.18(s, 2 H) 6.42(tt, 1H) 7.43(d, 2H) 7.49(dd, 1H) 7.62(d, 1H) 7.83(d, 1H) 7.91(d, 2H) 8.02(s, 1H)
36		4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]methyl}benzoic acid	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.79(dd, 2H) 2.38(qd, 1H) 2.49(qd, 1H) 2.80(dt, 1H) 3.26(dt, 1H) 3.79(d, 1H) 4.31(d, 1H) 4.45(td, 2H) 4.79(brs, 1H) 5.17(s, 2H) 6.42(tt, 1H) 7.40(d, 2H) 7.49(dd, 1H) 7.62(d, 1H) 7.83(d, 1H) 7.88(d, 2H) 8.02(s, 1H) 12.94(brs, 1H)
37		4-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]methyl}-N-(2-methoxyethyl)benzamide	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.72-1.82(m, 2H) 2.32-2.42(m, 1H) 2.44-2.54(m, 1H) 2.75-2.83(m, 1H) 3.21-3.29(m, 4H) 3.37-3.45(m, 4H) 3.77(br.d., 1H) 4.29(br.d., 1H) 4.44(td, 2H) 4.78(br.s., 1H) 5.14(s, 2H) 6.41(tt , 1H) 7.35(m, 2H) 7.48(dd, 1H) 7.61(d, 1H) 7.77(m, 2H) 7.81(d, 1H) 8.01(s, 1H) 8.47(t, 1H)

COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
38		4-[3-(3,4-dimethoxybenzyl)-6-methyl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.76(dd, 2H) 2.37(s, 3H) 2.39-2.42(m, 1H) 2.50-2.54(m, 1H) 2.77-2.82(m, 1H) 3.19-3.30(m, 1H) 3.70(s, 6H) 3.79(d, 1H) 4.30(d, 1H) 4.76(brs, 1H) 5.02(s, 2H) 6.82(dd, 1H) 6.85(d, 1H) 6.97(d, 1H) 7.60(dd, 1H) 7.71(d, 1H) 7.89(s, 1H) 8.03(s, 1H)
39		4-[6-(2,2-difluoroethoxy)-3-(3-hydroxy-4-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.70-1,80(m, 2H) 2.35-1,45(m, 1H) 2.47-2.56(m, 1H) 2.80(dt, 1H) 3.25(dt, 1H) 3.70(s, 3H) 3.79(brd, 1H) 4.30(brd, 1H) 4.43(td, 2H) 4.77(brs , 1H) 4.96(s, 2H) 6.41(tt, 1H) 6.73(d, 1H) 6.78-6.82(m, 2H) 7.46(dd, 1H) 7.60(d, 1H) 7.79(d, 1H) 8.03(s, 1H) 8.95 (s, 1 H)
40		4-[6-(2,2-difluoroethoxy)-3-[3-(2-hydroxyethoxy)-4-methoxybenzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (600 MHz, DMSO-d6) δ ppm 1.76(dd, 2H) 2.35-2.45(m, 1H) 2.50-2.54(m, 1H) 2.79(dt, 1H) 3.25(dt, 1H) 3.68(dt, 2H) 3.70(s, 3H) 3.79(brd, 1H) 3.90(t, 2H) 4.30(brd, 1H) 4.42(td, 2H) 4.75(brs, 1H) 4.77(t, 1H) 5.01(s, 2H) 6.39(tt, 1H) 6.85(m, 2H) 6.97(s, 1H) 7.45(dd, 1H) 7.60(d, 1H) 7.77(d, 1H) 8.02(s, 1H)
41		4-[6-(2,2-difluoroethoxy)-3-(3-ethoxy-4-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (600 MHz, DMSO-d_6) δ ppm 1.29(t, 3H) 1.76(dd, 2H) 2.33-2.45(m, 1H) 2.50-2.56(m, 1H) 2.76-2.82(m, 1H) 3.21-3.31(m, 1H) 3.70(s, 3H) 3.79(brd, 1H) 3.94(q, 2H) 4.30(brd,1 H) 4.41(dt, 2H) 4.75(brs , 1H) 5.01(s, 2H) 6.39(tt, 1H) 6.81-6.86(m, 2H) 6.96(s, 1H) 7.45(dd, 1H) 7.60(d, 1H) 7.77(d, 1H) 8.02(s, 1H)
42		4-[6-(2,2-difluoroethoxy)-3-[4-methoxy-3-(2-methoxyethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (600 MHz, DMSO-d_6) δ ppm 1.69-1.82(m, 2H) 2.35-2.45(m, 1H) 2.45-2.55(m, 1H) 2.78(t, 1H) 3.21-3.28(m, 1H) 3.61(brs, 2H) 3.70(s, 3H) 3.78(d, 1H) 4.00(brs, 2H) 4.30(d, 1H) 4.42(t, 2H) 4.75(brs, 1H) 5.01(s, 2H) 6.39(t, 1H) 6.82- 6.88(m, 2H) 6.97(s, 1H) 7.45(d, 1H) 7.59(s, 1H) 7.77(d, 1H) 8.02(s, 1H)






COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
43		4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]azepane-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) mixture of two isomers δ ppm 1.72-1.81(m, 1H) 1.85(brd, 1H) 1.86-2.03(m, 2H) 2.47(brs, 2H) 3.30-3.40(m, 1H) 3.42-3.52(m, 1H) 3.58-3.64(m, 2H) 3.70(s, 3H) 3.71(s, 3H) 4.42(td, 2H) 4.45(brs, 0.5H) 5.04(brs, 2H) 5.21(brs, 0.5H) 6.40(tt, 1H) 6.78-6.83(m, 1H) 6.86(d, 1H) 6.98(s, 1H) 7.38-7.48(m, 1H) 7.59(brs, 1H) 7.64-7.74(m, 1H) 8.08(brs, 0.5H) 8.12(s, 0.5H)
44		3-(3,4-dimethoxybenzyl)-2,4-dioxo-1-(pyrrolidin-3-yl)-1,2,3,4-tetrahydroquinazoline-6-carbonitrile	^{1}H NMR (600 MHz, DMSO-d_6) δ ppm 1.96-2.09(m, 2H) 2.78-2.84(m, 1H) 3.05-3.12(m, 2H) 3.18-3.27(m, 1H) 3.70(s, 3H) 3.71(s, 3H) 5.04(s, 2H) 5.47-5.53(m, 1H) 6.83(brs, 2H) 6.99(s, 1H) 8.15(dd, 1H) 8.20(d, 1H) 8.47(d, 1H)
45		1-(1-acetylpyrrolidin-3-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carbonitrile	^{1}H NMR (600 MHz, DMSO-d_6) mixture of two isomers δ ppm 1.91(s, 1.5H) 1.98(s, 1.5H) 2.14-2.22(m, 0.5H) 2.25-2.32(m, 0.5H) 2.43-2.50(m, 0.5H) 2.52-2.58(m, 0.5H) 3.31-3.39(m, 0.5H) 3.50-3.55(m, 0.5H) 3.63-3.73(m, 7.5H) 3.79-3.87(m, 1.5H) 5.00-5.06(m, 2H) 5.43-5.55(m, 1H) 6.82-6.90(m, 2H) 6.98(d, 1H) 7.84(dd, 1H) 8.17(dt, 1H) 8.43(dd, 1H)
46		3-(3,4-dimethoxybenzyl)-1-(1-formylpyrrolidin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carbonitrile	^{1}H NMR (500 MHz, DMSO-d_6) mixture of two isomers δ ppm 2.19-2.27(m, 1H) 2.36-2.43(m, 1H) 3.43-3.47(m, 0.4H) 3.53-3.59(m, 0.6) 3.62-3.73(m, 1.6H) 3.70(s, 3H) 3.71(s, 3H) 3.84-3.94(m, 1.4H) 5.04(s, 2H) 5.42-5.49(m, 0.4H) 5.50-5.56(m, 0.6H) 6.86(s, 2H) 6.99(s, 1H) 7.85(d, 0.6H) 7.90(d, 0.4H) 8.15-8.22(m, 2H) 8.45(s, 1H)
47		4-[6-(2,2-difluoroethoxy)-3-[3-(3-hydroxypropoxy)-4-methoxybenzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (600 MHz, DMSO-d_6) δ ppm 1.72-1.79(m, 2H) 1.82(q, 2H) 2.36-2.44(m, 1H) 2.49-2.55(m, 1H) 2.78(td, 1H) 3.25(td, 1H) 3.51-3.54(m, 2H) 3.70(s, 3H) 3.76-3.80(m, 1H) 3.95(t, 2H) 4.28-4.32(m, 1H) 4.41(td, 2H) 4.47(t, 1H) 4.75(s, 1H) 5.01(s, 2H) 6.39(tt, 1H) 6.81-6.86(m, 2H) 6.96-6.97(m, 1H) 7.45(dd, 1H) 7.59(d, 1H) 7.77(d, 1H) 8.02(s, 1H)






COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
48		4-[5-chloro-3-(3,4-dimethoxy benzyl)-2,4-dioxo-3,4-dihydro quinazolin-1(2H)-yl]piperidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.78-1.88(m, 2H) 2.34-2.44(m, 1H) 2.46-2.56(m, 1H) 2.80(t, 1H) 3.25(t, 1H) 3.71(s, 6H) 3.80(d, 1H) 4.31(d, 1H) 4.71(brs, 1H) 5.00(s, 2H) 6.83(d, 1H) 6.87(d, 1H) 6.97(s, 1H) 7.37(d, 1H) 7.69(dd, 1H) 7.77(d, 1H) 8.03(s, 1H)
49		4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(2,2-difluoro-ethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}-piperidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.5-1.6(m, 2H) 1.63-1.71(m, 3H) 1.68-1.78(m, 1H) 1.78-1.98(m, 3H) 2.35-2.46(m, 1H) 2.47-2.57(m, 1H) 2.79(dt, 1H) 3.26(dt, 1H) 3.69(s, 3H) 3.79(br.d., 1H) 4.30(br.d., 1H) 4.43(td, 2H) 4.66-4.70(m, 1H) 4.76(br.s., 1H) 5.01(s, 2H) 6.41(tt, 1H) 6.82 – 6.86(m, 2H) 6.96(s, 1H) 7.46(dd, 1H) 7.6(d, 1H) 7.80(d, 1H) 8.03(s, 1H)
50		2-(5-{[6-(2,2-difluoroethoxy)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]-methyl}-2-methoxyphenoxy)-acetamide	^{1}H NMR (500 MHz, DMSO-d_6) δ ppm 1.72-1.82(m, 2H) 2.35-2.45(m, 1H) 2.46-2.56(m, 1H) 2.79(td, 1H) 3.25(td, 1H) 3.74(s, 3H) 3.79(d, 1H) 4.31(d, 1H) 4.35(s, 2H) 4.43(td, 2H) 4.76(brs, 1H) 5.00(s, 2H) 6.41(tt, 1H) 6.88-6.95(m, 3H) 7.31(brs, 1H) 7.37(brs, 1H) 7.46(dd, 1H) 7.59(d, 1H) 7.79(d, 1H) 8.02(s, 1H)
51		4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]-3-methylpiperidine-1-carbaldehyde	^{1}H NMR (500 MHz, DMSO-d_6) mixture of two isomers δ ppm 0.92(t, 3H) 1.72-1.82(m, 1H) 2.23(brs, 1H) 2.70-2.77(m, 0.5H) 3.00-3.10(m, 0.5H) 3.12-3.20(m, 1.5H) 3.44(d, 0.5H) 3.63(dd, 0.5H) 3.69(s, 6H) 3.80(d, 0.5H) 4.04(d, 0.5H) 4.29(d, 0.5H) 4.43(td, 2H) 4.62-4.70(m, 1H) 5.03(s, 2H) 6.41(tt, 1H) 6.80(dd, 1H) 6.85(d, 1H) 6.97(d, 1H) 7.46(dd, 1H) 7.60(d, 1H) 7.64(dd, 1H) 7.97(s, 0.5H) 8.11(s, 0.5H)
52		3-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]-8-azabicyclo[3.2.1]octane-8-carbaldehyde	^{1}H NMR (600 MHz, DMSO-d_6) δ ppm 1.85-1.95(m, 4H) 2.18(t, 2H) 2.27-2.33(m, 1H) 2.34-2.41(m, 1H) 3.70(s, 1H) 3.71(s, 1H) 4.25-4.29(m, 1H) 4.40(td, 2H) 4.50-4.54(m , 1H) 4.55(br.s., 1H) 5.05(s, 2H) 6.38(tt, H) 6.80(d, 1H) 6.85(d, 1H) 6.98(s, 1H) 7.45(dd, 1H) 7.56(d, 1H) 7.58(d, 1H) 8.12(s, 1H)

COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
53		3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carbonitrile	^{1}H NMR (500 MHz, DMSO-d_6) mixture of two isomers δ ppm 1.52-1.63(m, 0.5H) 1.65-1.73(m, 0.5H) 1.74-1.83(m, 1H) 1.87-1.93(m, 1H) 2.54-2.64(m, 1.5H) 3.06(dt, 0.5H) 3.57(t, 0.5H) 3.70(s, 3H) 3.71(s, 3H) 3.79(dd, 0.5H) 4.03(t, 0.5H) 4.20(d, 0.5H) 4.30(d, 0.5H) 4.38(brs, 0.5H) 4.53(brs, 0.5H) 4.99-5.07(m, 2H) 6.84-6.88(m, 2H) 6.98(s, 1H) 7.86(d, 0.5H) 8.01(d, 0.5H) 7.98(s, 0.5H) 8.08(s, 0.5H) 8.14-8.18(m, 1H) 8.44(s, 1H)
54		1-(1-acetylpiperidin-3-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carbonitrile	^{1}H NMR (500 MHz, DMSO-d_6) mixture of two isomers δ ppm 1.56-1.66(m, 0.5H) 1.70-1.82(m, 1.5H) 1.87(brd, 1H) 1.97(s, 1.5H) 2.05(s, 1.5H) 2.54(dd, 1H) 3.05(brt, 0.5H) 3.48(t, 0.5H) 3.70-3.72(m, 6H) 3.83(d, 0.5H) 3.94(brd, 0.5H) 4.04(t, 0.5H) 4.33(brs, 0.5H) 4.45(dd, 1H) 4.53(brs, 0.5H) 4.99-5.07(m, 2H) 6.83-6.87(m, 2H) 6.98(d, 1H) 7.84(d, 0.5H) 8.02(d, 0.5H) 8.16(dt, 1H) 8.44(dd, 1H)
55		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	^{1}H NMR (600 MHz, DMSO-d_6) δ ppm 1.73-1.82(m, 2H) 2.36-2.44(m, 1H) 2.44-2.55(m, 1H) 2.79(td, 1H) 3.25(td, 1H) 3.80(brd, 1H) 4.32(brd, 1H) 4.62-4.67(m, 1H) 4.68-4.76(m, 3H) 4.76-4.82(m, 1H) 4.96-5.06(m, 1H) 7.44(dd, 1H) 7.61(d, 1H) 7.73(d, 1H) 8.03(s, 1H) 11.46(brs, 1H)
56		4-{3-[4-(cyclopentyloxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	LCMS m/z [MH]+ 572

COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
57		4-[3-(3-chlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 492
58		4-[3-(4-chlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 492
59		4-{3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	LCMS m/z [MH]+ 572
60		6-bromo-3-(3,4-dimethoxybenzyl)-1-[1-(hydroxyacetyl)piperidin-3-yl]quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 532
61		1-(1-acetylpiperidin-3-yl)-6-bromo-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 516






COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
62		3-(3,4-dimethoxybenzyl)-1-[1-(hydroxyacetyl)piperidin-3-yl]quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 454
63		6-bromo-3-(3,4-dimethoxybenzyl)-1-[piperidin-3-yl]quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 474
64		N-{[1-(1-acetylpyrrolidin-3-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide	LCMS m/z [MH]+ 495
65		3-[6-bromo-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 502
66		6-bromo-1-[1-(cyclopropylcarbonyl)piperidin-3-yl]-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 542
67		1-{1-[(benzyloxy)acetyl]piperidin-3-yl}-6-bromo-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 622






COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
68		1-{1-[(benzyloxy)acetyl]piperidin-3-yl}-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 638
69		3-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 518
70		3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-[1-(hydroxyacetyl)piperidin-3-yl]quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 548
71		3-[3-(3,4-dimethoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 484
72		4-[3-(3,4-dimethoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+484

COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
73		1-[1-(cyclopropylcarbonyl)-piperidin-3-yl]-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 558
74		4-[3-(3,4-dichlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 526
75		3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(piperidin-3-yl)quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 490
76		4-{3-[(6-chloropyridin-3-yl)methyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	LCMS m/z [MH]+ 493
77		N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpyrrolidin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide	LCMS m/z [MH]+ 481







COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
78		4-[3-(3-chloro-4-methoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)-ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 522
79		4-[3-(3,4-dimethoxybenzyl)-6-(2-fluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 486
80		6-bromo-3-(3,4-dimethoxybenzyl)-1-[pyrrolidin-3-yl]quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 460
81		6-bromo-1-[1-(cyclopropyl-carbonyl)pyrrolidin-3-yl]-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 528
82		1-(1-acetylpyrrolidin-3-yl)-6-bromo-3-(3,4-dimethoxybenzyl)-quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 502
83		3-[6-bromo-3-(3,4-dimethoxy-benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]pyrrolidine-1-carbaldehyde	LCMS m/z [MH]+ 488






COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
84		1-[1-(cyclopropylcarbonyl)-piperidin-3-yl]-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carbonitrile	LCMS m/z [MH]+ 489
85		3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(pyrrolidin-3-yl)quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 476
86		3-(3,4-dimethoxybenzyl)-1-[1-(hydroxyacetyl)piperidin-3-yl]-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-6-carbonitrile	LCMS m/z [MH]+ 479
87		1-[1-(cyclopropylcarbonyl)-pyrrolidin-3-yl]-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-carbonitrile	LCMS m/z [MH]+ 475
88		1-[1-[(benzyloxy)acetyl]pyrrolidin-3-yl]-6-bromo-3-(3,4-dimethoxybenzyl)quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 608




COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
89		2-[5-({6-[2-fluoro-1-(fluoro-methyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]acetamide	LCMS m/z [MH]+ 561
90		4-{6-[2-fluoro-1-(fluoro-methyl)ethoxy]-3-(3-hydroxy-4-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	LCMS m/z [MH]+ 504
91		4-[3-(3,4-dimethoxybenzyl)-6-ethoxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 468
92		1-[1-(cyclopropylcarbonyl)-pyrrolidin-3-yl]-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 544
93		1-{1-[(benzyloxy)acetyl]-pyrrolidin-3-yl}-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 624



COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
94		3-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]pyrrolidine-1-carbaldehyde	LCMS m/z [MH]+ 504
95		N-({1-[1-(cyclopropylcarbonyl)-pyrrolidin-3-yl]-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl}methyl)acetamide	LCMS m/z [MH]+ 521
96		3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-[1-(hydroxyacetyl)pyrrolidin-3-yl]quinazoline-2,4(1H,3H)-dione	LCMS m/z [M+Na]+ 534
97		4-[5,7-dichloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 492
98		1,1-dimethylethyl 3-{6-[(acetylamino)methyl]-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carboxylate	LCMS m/z [M+Na]+ 589









COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
99		N-[[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl]acetamide	LCMS m/z [MH]+ 495
100		N-[[1-(1-acetylpiperidin-3-yl)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl]acetamide	LCMS m/z [MH]+ 509
101		N-({1-[1-(cyclopropylcarbonyl)-piperidin-3-yl]-3-(3,4-dimethoxybenzyl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl}methyl)acetamide	LCMS m/z [MH]+ 535
102		4-[7-chloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 458
103		N-({3-(3,4-dimethoxybenzyl)-1-[1-(hydroxyacetyl)piperidin-3-yl]-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-6-yl}methyl)acetamide	LCMS m/z [MH]+ 525
104		3-(3,4-dimethoxybenzyl)-1-[1-(hydroxyacetyl)pyrrolidin-3-yl]-2,4-dioxo-1,2,3,4-tetrahydro-quinazoline-6-carbonitrile	LCMS m/z [MH]+ 465









COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
105		6-bromo-3-(3,4-dimethoxybenzyl)-1-[1-(hydroxyacetyl)pyrrolidin-3-yl]quinazoline-2,4(1H,3H)-dione	LCMS m/z [MH]+ 518
106		3-[3-(3,4-dimethoxybenzyl)-6-methyl-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]pyrrolidine-1-carbaldehyde	LCMS m/z [MH]+ 424
107		N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpyrrolidin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}formamide	LCMS m/z [MH]+ 467
108		4-{6-[2-fluoro-1-(fluoromethyl)-ethoxy]-3-(3-fluoro-4-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	LCMS m/z [MH]+ 506
109		4-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 530
110		1,1-dimethylethyl 3-[6-(benzyloxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]azetidine-1-carboxylate	LCMS m/z [MH]+ 574

COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
111		4-[6-(difluoromethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 490
112		4-[3-(3,4-dimethoxybenzyl)-6-(1-methylethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 482
113		1,1-dimethylethyl 3-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]azetidine-1-carboxylate	LCMS m/z [MH]+ 562
114		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-methoxy-3-(1-methylethoxy)-benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	LCMS m/z [MH]+ 546
115		1,1-dimethylethyl 3-[3-(3,4-dimethoxybenzyl)-6-hydroxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]azetidine-1-carboxylate	LCMS m/z [MH]+ 484









COMPOUND No.	STRUCTURE	NOMENCLATURE	NMR or MASS
116		4-{6-[2-fluoro-1-(fluoromethyl)-ethoxy]-3-(3-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	LCMS m/z [MH]+ 488
117		4-{3-[3,5-bis(trifluoromethyl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	LCMS m/z [MH]+ 564
118		4-[3-(3-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	LCMS m/z [MH]+ 502

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
119		4-[3-(3,4-dimethoxybenzyl)-6-hydroxy-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	440
120		1,1-dimethylethyl 3-({4-(benzyloxy)-2-[(3,4-dimethoxybenzyl)carbamoyl]phenyl}amino)azetidine-1-carboxylate	548

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
121		4-{3-[3-chloro-4-(cyclopentyloxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	576
122		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-fluoro-4-methylbenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	490
123		4-[3-(3,5-difluorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	494
124		4-{3-[3-chloro-4-(2-methoxyethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	566
125		4-{3-[(2-chloropyridin-4-yl)methyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	493
126		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(trifluoromethoxy)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	542
127		4-[3-(3,5-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	518
128		4-[3-(3-fluorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	476









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
129		4-[3-(4-fluorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	476
130		4-[3-(3,4-diethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	546
131		4-[3-(4-ethoxy-3-methoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	532
132		4-[3-(2,3-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	518
133		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-methoxy-3-methylbenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	502
134		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	526
135		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-phenoxybenzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	550
136		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(3-fluoropropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	534

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
137		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-nitrobenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	503
138		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-nitrobenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	503
139		1-(1-acetylazetidin-3-yl)-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione	504
140		4-[3-(2,5-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	518
141		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	488
142		4-{3-[3-(benzyloxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	564
143		4-{3-[4-(benzyloxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	594
144		4-[3-(3,5-dichlorobenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	526









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
145		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-nitrobenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	533
146		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{4-[(trifluoromethyl)sulphanyl]benzyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	558
147		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(pyrrolidin-1-ylmethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	541
148		1-[1-(cyclopropylcarbonyl)azetidin-3-yl]-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione	530
149		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(piperidin-1-ylmethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	555
150		3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-[1-(hydroxyacetyl)azetidin-3-yl]quinazoline-2,4(1H,3H)-dione	520
151		4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzonitrile	483
152		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[3-(trifluoromethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	526









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
153		3-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]azetidine-1-carbaldehyde	490
154		1-{1-[(benzyloxy)acetyl]azetidin-3-yl}-3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione	610
155		4-[3-(4-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	502
156		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[3-(piperidin-1-ylmethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	555
157		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-(morpholin-4-ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	557
158		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(morpholin-4-ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	557
159		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-(2-(morpholin-4-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	587
160		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	543









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
161		4-[3-(1-benzofur-6-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	498
162		1,1-dimethylethyl 4-[4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzyl]piperazine-1-carboxylate	656
163		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-methoxypyridin-3-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	489
164		4-{3-[3-chloro-4-(1-methylethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	550
165		4-[3-(biphenyl-4-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	534
166		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(methylsulphanyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	504
167		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-3-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	535
168		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-(pyrrolidin-1-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	527









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
169		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-fluoro-3-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	506
170		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-methylbenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	502
171		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-methyl-3-(trifluoromethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	540
172		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{4-[(4-methylpiperazin-1-yl)methyl]benzyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	570
173		4-[3-{4-(cyclopentyloxy)-3-[2-fluoro-1-(fluoromethyl)ethoxy]benzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	636
174		3-[3,4-bis(cyclopentyloxy)benzyl]-1-(1-ethenylpiperidin-4-yl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]quinazoline-2,4(1H,3H)-dione	626
175		2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]acetamide	615
176		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-(5-methyl-1,2,4-oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	540









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
177		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(methylsulphonyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	536
178		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-propoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	546
179		4-[3-(3-chloro-4-ethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	536
180		4-{3-[4-(1,1-dimethylethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	530
181		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[3-(trifluoromethoxy)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	542
182		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-fluoro-4-(trifluoromethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	544
183		2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N-methylacetamide	629
184		2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N,N-dimethylacetamide	643









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
185		2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N-methoxy-N-methylacetamide	659
186		4-{3-[4-(cyclopentyloxy)-3-ethoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	586
187		4-{3-[3-(cyclobutylmethoxy)-4-(cyclopentyloxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	626
188		4-{3-[4-(cyclopentyloxy)-3-(1-methylethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	600
189		4-{3-[4-(cyclopentyloxy)-3-propoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	600
190		4-{3-[4-(cyclopentyloxy)-3-hydroxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	558
191		4-{3-[4-(cyclopentyloxy)-3-(2-methylpropoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	614
192		4-[3-(1,3-benzodioxol-5-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	502









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
193		4-{3-[4-(difluoromethoxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	554
194		4-{3-[4-(difluoromethoxy)-3-ethoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	568
195		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-hydroxy-3-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	504
196		4-[3-(3,4-dihydro-2H-1,5-benzodioxepin-7-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	530
197		4-[3-(2,3-dihydro-1-benzofur-5-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	500
198		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-fluoro-5-(trifluoromethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	544
199		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-1H-benzotriazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	513
200		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-3-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	540

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
201		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-4-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	535
202		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(piperazin-1-ylmethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	555
203		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-1H-indol-6-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	511
204		4-{3-[3-chloro-4-(difluoromethoxy)-5-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	588
205		4-{3-[2-(difluoromethoxy)-3-ethoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	568
206		4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	558
207		2-[4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]-N-methylacetamide	575
208		4-[3-(biphenyl-3-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	534









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
209		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{3-[(4-methylpiperazin-1-yl)methyl]benzyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	570
210		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[3-(1H-1,2,4-triazol-1-yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	525
211		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(2-(morpholin-4-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	587
212		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1H-pyrazol-1-yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	524
213		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyridin-2-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	535
214		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-(piperidin-1-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	541
215		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	540
216		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(quinolin-7-ylmethyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	509

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
217		4-{3-[4-(difluoromethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	524
218		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-methoxynaphth-2-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	538
219		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[3-(1H-pyrazol-1-yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	524
220		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-(morpholin-4-yl)benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	543
221		4-[3-{4-[2-(dimethylamino)ethoxy]benzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	545
222		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-(2-methyl-1,3-thiazol-4-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	555
223		4-{3-[4-(1H-benzimidazol-1-yl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	574
224		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	560









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
225		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(piperidin-1-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	541
226		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(tetrahydrofuran-3-yloxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	574
227		4-{3-[4-(4-ethylpiperazin-1-yl)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	570
228		4-[3-{4-[(1-benzylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	663
229		4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl 1-methylethyl carbonate	590
230		4-[3-(1-benzothiophen-5-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	514
231		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(pyrrolidin-3-yloxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	573
232		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	546









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
233		4-[3-(3,4-dimethoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	536
234		4-[3-{4-[(1-acetylpyrrolidin-3-yl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	615
235		4-{3-[3-chloro-4-(cyclopropylmethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	562
236		4-{3-[3-chloro-4-(cyclobutylmethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	576
237		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-(morpholin-4-ylsulphonyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	607
238		4-[3-(3,4-diethoxybenzyl)-6-(difluoromethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	518
239		4-[3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	612
240		4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	628









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
241		4-[3-(1,3-benzothiazol-6-ylmethyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	515
242		4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	628
243		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(3-(thiophen-3-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	540
244		4-[3-(3,4-diethoxybenzyl)-6-(2,2-difluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	532
245		4-[3-(4-ethoxy-3-methoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	498
246		4-[3-{4-[2-(2,3-dihydro-1H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	663
247		4-[6-(2,2-difluoroethoxy)-3-(4-ethoxy-3-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	518
248		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-(pyridin-3-yl)benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	565

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
249		methyl 4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzoate	516
250		4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	662
251		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2-(piperidin-1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	629
252		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-(pyrimidin-5-yl)benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	566
253		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(4'-fluoro-2-methoxybiphenyl-4-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	582
254		4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	614
255		4-[3-(3,4-diethoxybenzyl)-6-(2-fluoroethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	514
256		4-[3-(3,4-dimethoxybenzyl)-6-(3-fluoro-2-hydroxypropoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	516

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
257		1,1-dimethylethyl 4-({4-[2-fluoro-1-(fluoromethyl)ethoxy]-2-(methoxycarbonyl)phenyl}amino)piperidine-1-carboxylate	429
258		4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(hydroxymethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	516
259		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[3-(1H-pyrazol-1-ylmethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	538
260		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-(thiophen-2-yl)benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	570
261		4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzoic acid	502
262		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[3-(1H-1,2,4-triazol-1-ylmethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	539
263		(2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid	630
264		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-(thiophen-2-yl)-1H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	544









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
265		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1H-1,2,4-triazol-1-ylmethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	539
266		4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-N-(2-(morpholin-4-yl)ethyl)benzamide	614
267		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(5-(thiophen-3-yl)-1,2,4-oxadiazol-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	532
268		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(4-methyl-2-phenylpyrimidin-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	550
269		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(5-(thiophen-2-yl)-1,2,4-oxadiazol-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	532
270		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	540
271		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-(thiophen-2-yl)-1,3-thiazol-4-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	547
272		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(2-fluoro-4-(thiophen-2-yl)benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	558

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
273		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-5-(thiophen-2-yl)-1H-pyrazol-3-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	544
274		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(3-(thiophen-2-yl)-1,2,4-oxadiazol-5-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	532
275		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	536
276		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-phenyl-1H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	538
277		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(5-phenyl-1,2,4-oxadiazol-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	526
278		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-{[6-(1H-pyrazol-1-yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	525
279		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-(thiophen-2-yl)pyrimidin-5-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	542
280		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(1-methyl-1H-pyrazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	538









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
281		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(imidazo[1,2-a]pyridin-7-ylmethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	598
282		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(3-methyl-1,2,4-oxadiazol-5-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	540
283		[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]acetic acid	616
284		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(5-(thiophen-2-yl)isoxazol-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	531
285		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(thieno[2,3-b]pyridin-2-ylmethyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	514
286		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-phenylpyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	535
287		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(6-(morpholin-4-yl)pyridin-3-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	544
288		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-phenyl-1,3-thiazol-4-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	541

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
289		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2-yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	541
290		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(2-(thiophen-2-yl)-1,3-oxazol-4-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	531
291		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	556
292		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-5-phenyl-1H-pyrazol-3-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	538
293		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	556
294		4-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile	559
295		(2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N-methylpropanamide	643
296		(2R)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N-phenylpropanamide	705

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
297		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(thiophen-2-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	558
298		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(morpholin-4-ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	587
299		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(piperidin-1-ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	585
300		4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	680
301		2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]-N-ethylacetamide	643
302		(2S)-2-[2-(cyclopentyloxy)-5-({6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenoxy]propanoic acid	630
303		4-[3-(3-fluoro-4,5-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	536
304		4-[3-(2-fluoro-4,5-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	536

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
305		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[(3R)-2-oxo-1-phenylpyrrolidin-3-yl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	663
306		4-{3-[4-(cyclobutylmethoxy)-3-methoxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	572
307		4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	612
308		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-hydroxy-3-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	522
309		4-{3-[4-(cyclopropylmethoxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	576
310		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-methylpropoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	578
311		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(1-methylethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	564
312		4-[3-(4-ethoxy-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	550









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
313		3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(6-oxopiperidin-3-yl)quinazoline-2,4(1H,3H)-dione	504
314		4-{6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(5-methoxy-1-methyl-4-oxo-1,4-dihydropyridin-2-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	519
315		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(3-methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	583
316		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(2-fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	571
317		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(4-fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	571
318		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(4-methoxyphenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	583
319		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[(6-(thiophen-2-yl)pyridin-3-yl)methyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	559
320		4-{3-[3-ethoxy-4-(thiophen-2-ylmethoxy)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	632









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
321		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(1-methyl-1H-pyrazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	556
322		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-(4-(pyrimidin-5-yl)benzyl)-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	554
323		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[(1-methyl-3-(thiophen-2-yl)-1H-pyrazol-5-yl)methyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	562
324		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-oxo-2-(piperidin-1-yl)ethoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	647
325		4-[3-{4-[2-(2,3-dihydro-1H-indol-1-yl)-2-oxoethoxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	681
326		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(5-methyl-1,2,4-oxadiazol-3-yl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	558
327		4-[3-{4-[(3-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	646
328		4-[3-{[6-(3,5-dichlorophenyl)pyridin-3-yl]methyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	603









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
329		4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)biphenyl-2-carbonitrile	577
330		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(1H-pyrazol-1-yl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	542
331		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{[6-(3-fluorophenyl)pyridin-3-yl]methyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	571
332		3-[5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)pyridin-2-yl]benzonitrile	578
333		4-[3-(3,4-diethoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	564
334		4-[3-{4-[(4-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	646
335		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(morpholin-4-ylmethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	575
336		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[6-(1H-pyrazol-1-yl)pyridin-3-yl]methyl}-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	543

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
337		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-(morpholin-4-yl)benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	561
338		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-propoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	564
339		4-{3-[4-(1H-benzimidazol-1-yl)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	592
340		5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxybenzonitrile	531
341		3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carbonitrile	543
342		4-[3-(4-bromobenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	554
343		4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-methoxyethoxy)benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	724
344		4-{3-[4-(benzyloxy)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	582









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
345		4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-ethoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	694
346		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-hydroxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	492
347		4-[3-{4-[(3,4-dichlorobenzyl)oxy]benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	650
348		4-{7-fluoro-3-[3-(2-fluoroethoxy)-4-hydroxybenzyl]-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	554
349		4-[3-{4-[(3,4-dichlorobenzyl)oxy]-3-(2-fluoroethoxy)benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	712
350		4-[3-{4-[(2-chloro-4-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	664
351		4-[3-{4-[(2,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	680
352		4-[3-{4-[(2-chloro-6-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	664









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
353		4-[3-{4-[(2,6-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	680
354		4-[3-{4-[(2-chlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	646
355		4-[7-fluoro-3-{4-[(2-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	630
356		4-[3-{3-[(3,4-dichlorobenzyl)oxy]benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	650
357		2-[(3,4-dichlorobenzyl)oxy]-5-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzonitrile	675
358		4-[3-{4-[(3,4-dichlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	680
359		4-{3-benzyl-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	476
360		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3-[4-(2-phenylethyl)benzyl]-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	580









COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
361		4-[3-(2-chloro-4,5-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	552
362		4-[3-{4-[(4,5-dichloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	698
363		4-[3-{3-[(3,4-dichlorobenzyl)oxy]-4-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	680
364		4-[3-(4-bromo-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	584
365		4-[3-{4-[(3,4-dichlorophenoxy)methyl]benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	650
366		4-[3-{4-[(4-chlorophenoxy)methyl]benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	616
367		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[3-methoxy-4-(2-phenylethyl)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	610
368		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	506








COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
369		4-[3-{4-[(4-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	646
370		4-{3-[4-(benzyloxy)-3-chlorobenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	616
371		4-[3-{3-chloro-4-[(4-chlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	694
372		4-[3-{4-[(2,4-dichlorobenzyl)oxy]benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	650
373		4-[3-{3-chloro-4-[(2,4-dichlorobenzyl)oxy]-5-ethoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	728
374		4-{3-[4-(benzyloxy)-3-chloro-5-ethoxybenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	660
375		4-[7-fluoro-3-{4-[(4-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	630
376		4-[3-{4-[(3,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	680

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
377		4-[3-(4-{[4-chloro-3-(trifluoromethyl)benzyl]oxy}-3-methoxybenzyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	714
378		4-[3-{4-[(3-chlorophenoxy)methyl]benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	616
379		4-[3-{4-[(3-chlorophenoxy)methyl]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	646
380		4-[3-{4-[(3,5-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	648
381		4-{3-[4-(benzyloxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	680
382		4-[3-{4-[(3-chloro-5-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	664
383		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(3-methoxy-4-{[4-(trifluoromethyl)benzyl]oxy}benzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	680
384		4-[3-{4-[(2,5-dichlorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	680

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
385		4-{[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]methyl}benzonitrile	637
386		3-{[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenoxy]methyl}benzonitrile	637
387		4-[3-{4-[(4-chloro-2-fluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	664
388		4-[3-{4-[1-(3,4-dichlorophenyl)ethoxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	694
389		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-{4-[(3-hydroxybenzyl)oxy]-3-methoxybenzyl}-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	696
390		4-[7-fluoro-3-{4-[(3-fluorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	630
391		4-[3-{4-[(3,4-difluorobenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	648
392		4-{3-[4-(5,6-dichloro-1H-benzimidazol-1-yl)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	660

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
393		4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)phenyl 3,4-dichlorobenzenesulphonate	700
394		4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl 3,4-dichlorobenzenesulphonate	730
395		4-{3-[4-(3,4-dichlorophenoxy)-3-methoxybenzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	666
396		N-(3,4-dichlorophenyl)-4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzamide	645
397		N-(3,4-dichlorobenzyl)-4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)benzamide	659
398		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-(4-{[3-fluoro-4-(trifluoromethyl)benzyl]oxy}-3-methoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	698
399		4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl 1-methylethyl carbonate	608
400		4-{3-[4-(4-chlorophenoxy)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	602

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
401		4-{3-[4-(3-chlorophenoxy)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	602
402		4-[3-{[1-(3,4-dichlorobenzyl)-1H-pyrazol-4-yl]methyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	624
403		3,4-dichloro-N-[4-({7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl}methyl)-2-methoxyphenyl]benzamide	693
404		4-[3-{4-[(4-chlorobenzyl)oxy]benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	616
405		4-{7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-3-[4-(4-fluorophenoxy)benzyl]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	586
406		4-{3-[4-(3,4-dichlorophenoxy)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	636
407		4-[3-({6-[(3,4-dichlorobenzyl)oxy]pyridin-3-yl}methyl)-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	651
408		4-[3-{4-[(2-chlorobenzyl)oxy]benzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	616

COMPOUND No.	STRUCTURE	NOMENCLATURE	MASS LCUVMS MH+
409		4-[3-{[1-(3,4-dichlorobenzyl)-1H-pyrazol-3-yl]methyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	624
410		4-[3-{[1-(3,4-dichlorobenzyl)-1H-indol-5-yl]methyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	673
411		3-{4-[(3,4-dichlorobenzyl)oxy]-3-methoxybenzyl}-6-[2-fluoro-1-(fluoromethyl)ethoxy]-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-7-carbonitrile	687
412		4-{3-[4-(5-chloro-6-fluoro-1H-benzimidazol-1-yl)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	644
413		4-{3-[4-(5-chloro-1H-benzimidazol-1-yl)benzyl]-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl}piperidine-1-carbaldehyde	626
414		4-[3-{4-[(4-chloro-2-methoxybenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	676
415		4-[3-{4-[(3-chloro-4-hydroxybenzyl)oxy]-3-methoxybenzyl}-7-fluoro-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	730

The compounds in accordance with the invention form the subject of pharmacological trials which have shown their advantage as therapeutically active substances.

1) Measurement of the inhibitory activity of the compounds in accordance with the invention with regard to PDE7

The ability of the compounds of formula (I) to inhibit PDE7 is measured using an enzymatic assay based on the separation of radioactive cAMP (substrate of PDE7) from the radioactive 5'-AMP (product of the enzymatic reaction) by thin layer chromatography on polyethyleneimine (PEI) cellulose, after halting the enzymatic reaction. The 5'-AMP is extracted quantitatively from the PEI cellulose and its radioactivity is measured using a liquid scintillation counter.

The inhibitory activity of the compounds of formula (I) with regard to PDE7 is represented by the inhibition constant IC_{50}, defined as the concentration of the compound (inhibitor) tested in the assay which makes it possible to reduce the enzymatic activity of PDE7 by 50%. The lower the IC_{50} values, the greater the inhibitory power of the compounds.

Materials

The [^{3}H]-cAMP (NET 275; 25 to 40 Ci/mmol) was purchased from Perkin-Elmer (NEN Life Sciences, Boston, United States), the rolipram was purchased from Sigma (St Louis, Mo, United States) and the sheets of polyethyleneimine cellulose F made of plastic for thin layer chromatography were purchased from Merck (Darmstadt, Germany). All the other products used are of commercial origin.

Enzyme

Human PDE7 was partially purified from the HUT-78 cell line by following a method analogous to that described by Bloom and Beavo (Proc. Natl. Acad. Sci. USA, (1996) 93, 14188-14192). The enzyme preparation obtained is stored at -80°C in a buffer comprising 20 mM of Tris-HCl (pH 7.0), 5 mM of $MgCl_2$, 4 mM of EDTA, 1 mM of dithiothreitol and 20% of glycerol. As the partially purified PDE7 is contaminated by PDE4, it is necessary to add 10 µM of rolipram (selective inhibitor of PDE4) in the enzymatic assay in order to completely inhibit the PDE4 activity. The Michaelis constant (Km) of PDE7 for cAMP, measured using the radiochemical assay described below, is 21 nM.

Solutions of compounds in accordance with the invention

The compounds of formula (I) to be tested as PDE7 inhibitors are dissolved in

DMSO at a concentration of 10 mM. These solutions are subsequently diluted in cascade in DMSO in order to obtain solutions with the desired concentrations. The latter are subsequently diluted to one-twentieth in the assay buffer to give 5% DMSO solutions. The latter are finally diluted to one-fifth in the enzymatic assay.

The solution of rolipram (added in the assay in order to completely inhibit the contaminating PDE4 activity) is prepared in an identical way and contributes 1% of DMSO to the enzymatic assay.

PDE7 Enzymatic assay

The assay is carried out in 1.5 ml Eppendorf tubes comprising 40 mM of Tris-HCl (pH 7.5), 15 mM of $MgCl_2$, 1 mM of EGTA, 0.5 mg/ml of bovine serum albumin, 0.063 µCi of [^{3}H]-cAMP (corresponding to a cAMP concentration of between 15 and 25 nM), 10 µM of rolipram and PDE7 in a final volume of 100 µl. The assay is carried out in the absence (control sample) or in the presence (treated sample) of the compounds tested as PDE7 inhibitors. The final concentration of DMSO in the assay is 2%. The reaction is initiated by addition of enzyme and the samples are maintained at ambient temperature for 30 minutes. The enzymatic dilution is adjusted so as to obtain a degree of conversion of 10 to 15%. The enzymatic reaction is halted by immersion of the stoppered Eppendorf tubes in a water bath at 100°C for 3 minutes. Blanks (reaction halted immediately after addition of the enzyme) are included in each experiment. The samples are subsequently centrifuged at 10 000xg for 1 minute and an aliquot portion of 10 µl of supernatant is deposited 2 cm from the bottom edge of a sheet of PEI cellulose on which 10 µg of cAMP and 10 µg of 5'-AMP have been deposited beforehand. In order to facilitate the migration and to make it easier to cut out the strips of PEI cellulose comprising the 5'-AMP, which take place subsequently, 18 migration lanes with a width of 1 cm are delimited per plate by scraping the cellulose with a spatula over a width of 1 mm. The plates are developed over their entire length with a 0.30 M solution of LiCl in water by ascending chromatography. The 5'-AMP (Rf = 0.20) and the cAMP (Rf = 0.47) are visualized under UV light at 254 nm. The strips of PEI cellulose comprising the 5'-AMP are cut out and the nucleotide is quantitatively extracted in counting flasks with 2 ml of a solution which is 16M in formic acid and 2M in ammonium formate in water (rotary stirrer for 15 min). After addition of 10 ml of scintillation liquid (OptiPhase HiSafe 3 from Perkin-Elmer/Wallac), the radioactivity is counted using a liquid scintillation counter (model 1414, Perkin-Elmer/Wallac). Each assay is carried out in duplicate. The radioactivity specifically associated with the 5'-AMP formed in the enzymatic reaction is obtained by subtracting the mean value of blanks from the mean value of the controls (or treated samples).

The percentage of inhibition of PDE7 at a given concentration of the compound tested (inhibitor) is calculated using the equation : I% = [mean value of the controls – mean value of the treated samples] x 100/[mean value of the controls – mean value of the blanks].

The IC_{50} is the concentration of the compound (inhibitor) tested in the assay which makes it possible to reduce the enzymatic activity of PDE7 by 50%.

Results

As illustrative and nonlimiting examples, the following quinazolinediones inhibit PDE7 with the IC_{50} values indicated below :

Compound	IC_{50} (μM)
No. 16: 4-[6-(2,2-difluoroethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	0.015
No. 11: 4-[3-(3,4-dimethoxybenzyl)-6-[2-fluoro-1-(fluoromethyl)ethoxy]-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	0.039
No. 72: 4-[3-(3,4-dimethoxybenzyl)-6-(2-hydroxyethoxy)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	0.089
No. 77: N-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpyrrolidin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]methyl}acetamide	0.82
No. 97: 4-[5,7-dichloro-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	0.061
No. 111: 4-[6-(difluoromethoxy)-3-(3,4-dimethoxybenzyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl]piperidine-1-carbaldehyde	0.0067

2) Measurement of the inhibitory activity of the compounds in accordance with the invention with regard to PDE8

By using for PDE8 an enzymatic assay equivalent to that described for PDE7, the following IC_{50} values are obtained :

Compound	IC_{50} PDE7 (μM)	IC_{50} PDE8 (μM)
No. 11	0.039	0.14
No. 251	0.046	0.39
No. 294	0.037	0.015

3) Evaluation of the compounds in accordance with the invention in an in vitro model of microglial activation

The glial cells actively participate in the neurodegenerative mechanism by the production of neurotoxic factors. The production of these mediators forms part of the neuroinflammatory process observed in neurodegenerative diseases and in particular in Parkinson's disease and Alzheimer's disease.

Numerous studies have demonstrated that the inhibition of glial activation and consequently the reduction in the production of proinflammatory factors, such as interleukin-1, released by activated glial cells significantly reduces neuronal degeneration.

The compounds according to the invention have been evaluated in an in vitro model of microglial activation. After activation by lipopolysaccharide (LPS), the microglial cells secrete large amounts of interleukin-1, which amounts can be quantified by specific assaying in the cell supernatants.

Cultures of microglial cells of the MG7 line derived from the mouse cortex are incubated in the presence of variable concentrations of compounds according to the invention. After incubating at 37°C for 1 hour, the cells are brought together with LPS, which induces the production of interleukin-1. After treating for 24 h, the amounts of interleukin-1β are measured in the culture supernatants by ELISA assay.

Compound No. 297 significantly decreases, in a concentration-dependent fashion, the secretion of interleukin-1β by MG7 microglial cells activated by LPS. The maximum inhibitory effect observed is 47% at 3 μM.

According to the invention, the compound of formula (I) defined above in accordance with the invention can be used as medicament or in the preparation of a medicament intended for the treatment and/or prevention of disorder(s) related to the central nervous system and/or related to the peripheral nervous system.

According to the invention, the compound of formula (I) in accordance with the invention can be used as medicament or in the preparation of a medicament intended for the treatment and/or prevention of psychiatric disorder(s) and/or neurological disorder(s).

According to the invention, the compounds of formula (I) in accordance with the invention can be used as medicaments or in the preparation of a medicament intended for the treatment or prevention of psychiatric disorders chosen from anxiety, depression, mood disorders, insomnia, delusion disorders, obsessive disorders, psychoses, disorders related to schizophrenia, attention deficit hyperactivity disorders (ADHD) in hyperkinetic children, disorders related to the use of psychotropic substances, in particular in the case

of abuse of a substance and/or of dependency on a substance, including alcohol dependence and/or nicotine dependence, migraine, stress, disorders related to illnesses of psychosomatic origin, panic attacks, epilepsy, memory disorders, cognitive disorders, in particular senile dementia or disorders related to Alzheimer's disease, and disorders of attention or of vigilance, ischaemia, disorders related to brain trauma or disorders related to acute or chronic neurodegenerative diseases, including chorea and Huntington's chorea.

According to the invention, the compounds of formula (I) in accordance with the invention can be used as medicaments or in the preparation of a medicament intended for the treatment and/or prevention of neurological disorders which may be reflected by movement anomalies or motor disorders associated with a pathology chosen from dyskinesia, Parkinson's disease, postencephalitic parkinsonism, dopa-sensitive dystonia, Shy-Drager syndrome, periodic limb movement disorder (PLMD) syndrome, periodic limb movements in sleep (PLMS) syndrome, Tourette's syndrome or restless legs syndrome (RLS).

According to one embodiment, the compounds of formula (I) in accordance with the invention can be used as medicaments or to manufacture a medicament intended for the treatment of at least one movement anomaly or motor disorder related to Parkinson's disease; in particular, the said movement anomaly or the said motor disorder is chosen from resting tremor, rigidity, bradykinesia and deficiency in postural reflexes.

According to one embodiment, the compounds of formula (I) in accordance with the invention can be used as medicaments or for manufacturing a medicament intended for the prevention and/or treatment of neurological disorders reflected by movement anomalies or motor disorders associated with trauma of the spinal cord, in particular in the treatment of spinal trauma. Within the meaning of the present invention, the term "trauma of the spinal cord" is understood to mean acute or chronic pathologies which have an external origin and which destroy the spinal tract and/or spinal neurones, and which occur, for example, during a fall, impact, crushing episode or road crash.

Advantageously, the compounds of formula (I) in accordance with the invention can be used as medicaments or to manufacture a medicament intended for the prevention and/or treatment of disorders:

- related to schizophrenia, in particular (i) in the prevention and/or treatment of positive or negative symptoms and/or (ii) in the prevention and/or treatment of memory

deficiency;

- associated with Parkinson's disease, in particular (i) in the symptomatic prevention and/or treatment of motor disorders, depression and/or cognitive disorders and/or (ii) in its basic (neuroprotective) treatment and/or

- related to Alzheimer's disease, in particular (i) in the symptomatic prevention and/or treatment of cognitive disorders and/or behavioural disorders (aggression, depression) and/or (ii) in its basic (neuroprotective) treatment.

The use of the compounds of general formula (I) in accordance with the invention as medicaments or to manufacture a medicament intended to treat and/or prevent the abovementioned disorders or pathologies forms an integral part of the invention, and in particular compounds of formula (I) chosen from compounds Nos. 1 to 6, 11 to 14, 16, 20, 22 to 25, 32 to 43, 47 to 52, 55 to 59, 72, 74, 76, 78, 79, 89 to 91, 97, 102, 108, 111, 112, 114, 116 to 118, 124, 130, 131, 133 to 135, 143, 145, 155, 158, 160, 165 to 167, 170, 175, 178, 183 to 186, 188, 189, 190, 193, 194, 200, 201, 203, 206, 207, 212, 213, 215, 216, 218, 223, 224, 226, 228, 230, 232 to 234, 239, 240, 242, 243, 245, 246, 250, 251, 254, 258, 263, 264, 270, 275, 276, 278 to 280, 282, 283, 285 to 287, 289, 292, 294, 295, 287 to 302, 305 to 312, 315 to 345, 349 to 355, 357, 358, 360, 362, 369, 371, 373, 375 to 377, 379 to 394 and 403.

Another subject-matter of the invention is a compound corresponding to the general formula (I) as defined above in the treatment and/or prevention of disorders related to the central nervous system and/or related to the peripheral nervous system, the said disorder(s) advantageously being chosen from psychiatric disorders and neurological disorders.

Pharmaceutical compositions comprising, as active principle, at least one compound in accordance with the invention are of use in the present invention. These pharmaceutical compositions comprise an effective dose of at least one compound of formula (I) in accordance with the invention and also at least one pharmaceutically acceptable excipient.

The said excipients are chosen, according to the pharmaceutical form and the method of administration desired, from the usual excipients which are known to a person skilled in the art.

In the pharmaceutical compositions of use in the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active principle of formula (I) above

or its optional salt, solvate or hydrate can be administered in unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and human beings for the prophylaxis or treatment of the above disorders or diseases.

The appropriate unit administration forms comprise forms by the oral route, such as tablets, soft or hard gelatin capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular or intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants. Use may be made, for topical application, of the compounds according to the invention in creams, gels, ointments or lotions.

By way of example, a unit administration form of a compound in accordance with the invention in the form of a tablet can comprise the following components :

Compound No. 1 (2-{[3-(3,4-dimethoxybenzyl)-1-(1-formylpiperidin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl]oxy}propanenitrile)	50.0 mg
Mannitol	223.75 mg
Croscarmellose sodium	6.0 mg
Maize starch	15.0 mg
Hydroxypropylmethylcellulose	2.25 mg
Magnesium stearate	3.0 mg


The said unit forms comprise doses in order to make possible daily administration of 0.5 mg to 800 mg of active principle per individual, more particularly of 0.5 mg to 200 mg, according to the pharmaceutical dosage form.

There may be cases where higher or lower dosages are appropriate ; such dosages do not depart from the scope of the invention. According to the usual practice, the dosage appropriate to each patient is determined by the physician according to the method of administration and the weight and response of the said patient.

A method for the treatment and/or prevention of the pathologies indicated above comprises the administration, to a patient, of an effective dose of a compound in accordance with the invention or of one of its hydrates or solvates.

CLAIMS

1. Use of a compound corresponding to the general formula (I)



(I)

in which

— A represents an aryl group or a heteroaryl group;

— R_1 represents:

■ a hydrogen atom,

■ -C(O)R in which R is a hydrogen atom, a (C_1-C_6) alkoxy group, an aryl group, a (C_3-C_6) cycloalkyl group or a (C_1-C_6) alkyl group, the said alkyl optionally being substituted by:

. one or more hydroxyl group(s),

. a benzyloxy group,

. a (C_1-C_6) alkoxy group, optionally substituted by an aryl, or

. a (C_3-C_6) cycloalkyl group,

■ an optionally substituted (C_1-C_6) alkyl group;

— R_2 represents:

■ a hydrogen atom,

■ a halogen atom,

■ a cyano group,

■ a nitro group,

■ a (C_1-C_6) alkyl group optionally substituted by an $-NH_2$ or else by an -NHC(O)Rb group, with Rb as defined below,

■ an -ORa group in which Ra represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s),

. a (C_2-C_6) alkynyl group,

. an aryl group;

— R_3 represents:

- a hydrogen atom,
- a halogen atom,
- a hydroxyl group,
- a cyano group,
- an $-SCF_3$ group,
- a nitro group,
- an oxo group,
- an $-S(O)_{0-2}$-alkyl group, an $-S(O)_{0-2}$-heterocycloalkyl group, an $-O-SO_2$-aryl group optionally substituted by one or more halogen atom(s);
- an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl,
- an optionally substituted sulphonamide group,
- an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C_1-C_6) alkyl group, by one or more halogen atom(s) or by a (C_1-C_6) alkoxy group,
- a heterocycloalkyl group optionally substituted by a (C_1-C_6) alkyl group,
- a (C_1-C_6) alkyl group optionally substituted by:
  - one or more halogen atom(s),
  - an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s),
  - a heteroaryl group,
  - one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or
  - a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C_1-C_6) alkyl group, with Ra as defined above,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- a -C(O)ORc group or an $-O-C(O)ORc$ group, with Rc as defined below,
- a (C_1-C_6) alkoxy group, optionally substituted by
  - an aminoalkyl group,
  - an aminocycloalkyl group,

- a cycloalkyl group,
- a heterocycloalkyl group,
- a monocyclic or polycyclic heteroaryl group,
- one or more hydroxyl group(s),
- one or more halogen atom(s),
- a (C_1-C_6) alkoxy group,
- a –C(O)ORc group, with Rc as defined below,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- an oxo group, and/or
- an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C_1-C_6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group,

■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by

- an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C_1-C_6) alkyl group,
- an oxo group,
- one or more halogen atom(s), and/or
- a (C_1-C_6) alkyl group, which can itself be substituted by an aryl group and/or an oxo group,

■ an –NH-CO-NH-aryl group, an –NH-CO-NH-heteroaryl group or an –NH-CO-NH-(C_1-C_6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C_1-C_6) alkoxy group,

■ an –N-(C_1-C_6) alkyl group, it being possible for the (C_1-C_6) alkyl group to be substituted by

- one or more oxo group(s), and/or
- one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO_2 group,

■ an –NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s);

or else R_3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C_1-C_6) alkoxy group or a (C_1-C_6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s);

— R_4 represents a hydrogen atom, an oxo group or a (C_1-C_6) alkyl group;

— Rb represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl, cyano, amino, heterocycloalkyl or (C_1-C_6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s),

. a (C_3-C_6) cycloalkyl group,

. a (C_2-C_6) alkynyl group,

. a (C_1-C_6) alkoxy group,

. an aryl group optionally substituted by one or more halogen atom(s);


— Rc represents a hydrogen atom or a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s);

or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group;

— m and n represent, independently of one another, the value 0, 1 or 2, it being understood that m+n≤3;

— p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R_2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R_3 groups are on separate carbon atoms and can be different from one another;

— q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type:




with R_1, R_4, m and n as defined above,

— r represents the value 0 or 1;

in the form of the base or of an addition salt with an acid;

in the preparation of a medicament intended for the treatment and/or prevention of disorder(s) related to the central nervous system and/or related to the peripheral nervous system.

2. Use of a compound corresponding to the general formula (I)



(I)

in which

— A represents an aryl group or a heteroaryl group;

— R_1 represents:

■ a hydrogen atom,

■ -C(O)R in which R is a hydrogen atom, a (C_1-C_6) alkoxy group, an aryl group, a (C_3-C_6) cycloalkyl group or a (C_1-C_6) alkyl group, the said alkyl optionally being substituted by:

. one or more hydroxyl group(s),

. a benzyloxy group,

. a (C_1-C_6) alkoxy group, optionally substituted by an aryl, or

. a (C_3-C_6) cycloalkyl group,

■ an optionally substituted (C_1-C_6) alkyl group;

— R_2 represents:

■ a hydrogen atom,

■ a halogen atom,

■ a cyano group,

■ a nitro group,

■ a (C_1-C_6) alkyl group optionally substituted by an $-NH_2$ or else by an -NHC(O)Rb group, with Rb as defined below,

■ an -ORa group in which Ra represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s),

. a (C_2-C_6) alkynyl group,

. an aryl group;

— R_3 represents:

■ a hydrogen atom,

■ a halogen atom,

■ a hydroxyl group,

■ a cyano group,

■ an $-SCF_3$ group,

■ a nitro group,

■ an oxo group,

■ an $-S(O)_{0-2}$-alkyl group, an $-S(O)_{0-2}$-heterocycloalkyl group, an $-O-SO_2$-aryl group optionally substituted by one or more halogen atom(s);

■ an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl,

■ an optionally substituted sulphonamide group,

■ an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C_1-C_6) alkyl group, by one or more halogen atom(s) or by a (C_1-C_6) alkoxy group,

■ a heterocycloalkyl group optionally substituted by a (C_1-C_6) alkyl group,

■ a (C_1-C_6) alkyl group optionally substituted by:

- one or more halogen atom(s),

- an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s),

- a heteroaryl group,

- one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or

- a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C_1-C_6) alkyl group, with Ra as defined above,

■ a -C(O)NRbRc group, with Rb and Rc as defined below,

■ a -C(O)ORc group or an –O-C(O)ORc group, with Rc as defined below,

■ a (C_1-C_6) alkoxy group, optionally substituted by

- an aminoalkyl group,
- an aminocycloalkyl group,
- a cycloalkyl group,
- a heterocycloalkyl group,
- a monocyclic or polycyclic heteroaryl group,
- one or more hydroxyl group(s),
- one or more halogen atom(s),
- a (C_1-C_6) alkoxy group,
- a –C(O)ORc group, with Rc as defined below,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- an oxo group, and/or
- an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C_1-C_6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group,

■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by

- an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C_1-C_6) alkyl group,
- an oxo group,
- one or more halogen atom(s), and/or
- a (C_1-C_6) alkyl group, which can itself be substituted by an aryl group and/or an oxo group,

■ an –NH-CO-NH-aryl group, an –NH-CO-NH-heteroaryl group or an –NH-CO-NH-(C_1-C_6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C_1-C_6) alkoxy group,

■ an –N-(C_1-C_6) alkyl group, it being possible for the (C_1-C_6) alkyl group to be substituted by

- one or more oxo group(s), and/or
- one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO_2 group,

■ an –NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s);

or else R_3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C_1-C_6)

alkoxy group or a (C_1-C_6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s);

— R_4 represents a hydrogen atom, an oxo group or a (C_1-C_6) alkyl group;

— Rb represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl, cyano, amino, heterocycloalkyl or (C_1-C_6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s),

. a (C_3-C_6) cycloalkyl group,

. a (C_2-C_6) alkynyl group,

. a (C_1-C_6) alkoxy group,

. an aryl group optionally substituted by one or more halogen atom(s);


— Rc represents a hydrogen atom or a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s);

or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group;

— m and n represent, independently of one another, the value 0, 1 or 2, it being understood that $m+n \leq 3$;

— p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R_2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R_3 groups are on separate carbon atoms and can be different from one another;

— q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type:



with R_1, R_4, m and n as defined above,

— r represents the value 0 or 1;

in the form of the base or of an addition salt with an acid;

as medicament.

3. Use according to either of the preceding claims, characterized in that the disorder(s) is or are chosen from psychiatric disorders and neurological disorders.

4. Use according to Claim 3, characterized in that the psychiatric disorders are chosen from anxiety, depression, mood disorders, insomnia, delusion disorders, obsessive disorders, psychoses, disorders related to schizophrenia, attention deficit hyperactivity disorders (ADHD) in hyperkinetic children, disorders related to the use of psychotropic substances, in particular in the case of abuse of a substance and/or of dependency on a substance, including alcohol dependence and/or nicotine dependence, migraine, stress, disorders related to illnesses of psychosomatic origin, panic attacks, epilepsy, memory disorders, cognitive disorders, in particular senile dementia or disorders related to Alzheimer's disease, and disorders of attention or of vigilance, ischaemia, disorders related to brain trauma or disorders related to acute or chronic neurodegenerative diseases, including chorea and Huntington's chorea.

5. Use according to Claim 3, characterized in that the neurological disorders are reflected by movement anomalies or motor disorders associated with a pathology chosen from dyskinesia, Parkinson's disease, postencephalitic parkinsonism, dopa-sensitive dystonia, Shy-Drager syndrome, periodic limb movement disorder (PLMD) syndrome, periodic limb movements in sleep (PLMS) syndrome, Tourette's syndrome or restless legs syndrome (RLS).

6. Use according to Claim 5, characterized in that the movement anomalies or motor disorders are associated with Parkinson's disease.

7. Use according to Claim 6, characterized in that the anomalies or motor disorders are chosen from resting tremor, rigidity, bradykinesia and deficiency in postural reflexes.

8. Use according to one of Claims 4 to 7, (a) in the treatment and/or prevention of disorders related to schizophrenia, in particular (i) in the prevention and/or treatment of positive or negative symptoms and/or (ii) in the prevention and/or treatment of memory deficiency, (b) in the treatment and/or prevention of disorders associated with Parkinson's disease, in particular (i) in the symptomatic prevention and/or treatment of motor disorders, depression and/or cognitive disorders and/or (ii) in its basic treatment, and/or (c) in the treatment and/or prevention of disorders related to Alzheimer's disease, in particular (i) in the symptomatic prevention and/or treatment of cognitive disorders and/or behavioural disorders and/or (ii) in its basic treatment.

9. Use according to Claim 3, characterized in that the neurological disorders are reflected by movement anomalies or motor disorders associated with trauma of the spinal cord, in particular spinal trauma.

10. Use according to any one of the preceding claims, characterized in that A represents a phenyl group or a pyridyl group.

11. Use according to any one of the preceding claims, characterized in that q = 0, and m and n each represents 1.

12. Use according to any one of the preceding claims, characterized in that R_2 represents a (C_1-C_6) alkyl group, in particular a methyl, substituted by an –NH-C(O)-Rb group, Rb being as defined in Claim 1 or Claim 2.

13. Use according to any one of Claims 1 to 11, characterized in that R_2 represents an –ORa group, Ra being as defined in Claim 1 or Claim 2.

14. Use according to any one of Claims 1 to 11, characterized in that R_2 is a halogen atom or a cyano or a hydrogen or a hydroxyl or a (C_1-C_6) alkyl optionally substituted by an $–NH_2$ or else by an –NHC(O)Rb group, Rb being as defined in Claim 1 or Claim 2.

15. Use according to any one of Claims 1 to 11, characterized in that A is a phenyl, R_1 is a –C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1 and R_2 represents –ORa, Ra being as defined in Claim 1 or Claim 2.


16. Use according to any one of Claims 1 to 11, characterized in that A is a phenyl, R_1 is a –C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p = 1 and R_2 represents a methyl substituted by an -NH-CO-Rb group, Rb being as defined in Claim 1 or Claim 2.

17. Use according to any one of Claims 1 to 11, characterized in that A is a phenyl, R_1 is a –C(O)R group in which R represents a hydrogen atom, q is equal to 0, n and m each have the value 1, p is equal to 2, one of the R_2 groups is –ORa, Ra being as defined in Claim 1 or Claim 2, and the other of the R_2 groups is a halogen atom.

18. Use according to any one of the preceding claims, characterized in that the R_2 group is in the 6 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system and in that there may additionally be an R_2 group, identical to or different from the said abovementioned R_2 group, in the 7 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system, the said compound of formula (I) being in the base, hydrate or solvate form, in the form of isomers or in the form of their mixtures.

19. Use according to any one of Claims 1 to 9, characterized in that the compound of formula (I) is chosen from compounds Nos. 1 to 6, 11 to 14, 16, 20, 22 to 25, 32 to 43, 47 to 52, 55 to 59, 72, 74, 76, 78, 79, 89 to 91, 97, 102, 108, 111, 112, 114, 116 to 118, 124, 130, 131, 133 to 135, 143, 145, 155, 158, 160, 165 to 167, 170, 175, 178, 183 to 186, 188, 189, 190, 193, 194, 200, 201, 203, 206, 207, 212, 213, 215, 216, 218, 223, 224, 226, 228, 230, 232 to 234, 239, 240, 242, 243, 245, 246, 250, 251, 254, 258, 263, 264, 270, 275, 276, 278 to 280, 282, 283, 285 to 287, 289, 292, 294, 295, 287 to 302, 305 to 312, 315 to 345, 349 to 355, 357, 358, 360, 362, 369, 371, 373, 375 to 377, 379 to 394 and 403, in the form of the base or of an addition salt with an acid.

20. Compound corresponding to the general formula (I)



(I)

in which

— A represents an aryl group or a heteroaryl group;

— R_1 represents:

■ a hydrogen atom,

■ -C(O)R in which R is a hydrogen atom, a (C_1-C_6) alkoxy group, an aryl group, a (C_3-C_6) cycloalkyl group or a (C_1-C_6) alkyl group, the said alkyl optionally being substituted by:

. one or more hydroxyl group(s),

. a benzyloxy group,

. a (C_1-C_6) alkoxy group, optionally substituted by an aryl, or

. a (C_3-C_6) cycloalkyl group,

■ an optionally substituted (C_1-C_6) alkyl group;

— R_2 represents:

■ a hydrogen atom,

■ a halogen atom,

■ a cyano group,

■ a nitro group,

■ a (C_1-C_6) alkyl group optionally substituted by an $-NH_2$ or else by an -NHC(O)Rb group, with Rb as defined below,

■ an -ORa group in which Ra represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by one or more hydroxyl group(s), by an aryl group and/or by one or more cyano group(s),

. a (C_2-C_6) alkynyl group,

. an aryl group;

— R_3 represents:

- a hydrogen atom,
- a halogen atom,
- a hydroxyl group,
- a cyano group,
- an $-SCF_3$ group,
- a nitro group,
- an oxo group,
- an $-S(O)_{0-2}$-alkyl group, an $-S(O)_{0-2}$-heterocycloalkyl group, an $-O-SO_2$-aryl group optionally substituted by one or more halogen atom(s);
- an -alkylaminoalkyl or -cycloalkylaminoalkyl group, each optionally substituted on the end alkyl,
- an optionally substituted sulphonamide group,
- an aryl group or a heteroaryl group, the said group being monocyclic or polycyclic and in addition optionally being substituted by a (C_1-C_6) alkyl group, by one or more halogen atom(s) or by a (C_1-C_6) alkoxy group,
- a heterocycloalkyl group optionally substituted by a (C_1-C_6) alkyl group,
- a (C_1-C_6) alkyl group optionally substituted by:
  - one or more halogen atom(s),
  - an aryl group which can be substituted by one or more halogen atom(s) or by one or more hydroxyl group(s),
  - a heteroaryl group,
  - one or more hydroxyl group(s) which can be substituted by an aryl group itself optionally substituted by one or more halogen atom(s), or
  - a heterocycloalkyl group optionally substituted by a CO(O)Ra group or by a (C_1-C_6) alkyl group, with Ra as defined above,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- a -C(O)ORc group or an $-O-C(O)ORc$ group, with Rc as defined below,
- a (C_1-C_6) alkoxy group, optionally substituted by
  - an aminoalkyl group,
  - an aminocycloalkyl group,
  - a cycloalkyl group,
  - a heterocycloalkyl group,
  - a monocyclic or polycyclic heteroaryl group,
  - one or more hydroxyl group(s),

- one or more halogen atom(s),
- a (C_1-C_6) alkoxy group,
- a –C(O)ORc group, with Rc as defined below,
- a -C(O)NRbRc group, with Rb and Rc as defined below,
- an oxo group, and/or
- an aryl group, itself optionally substituted by one or more halogen atom(s), a cyano group, a (C_1-C_6) alkoxy group, an -O-haloalkyl group and/or a haloalkyl group,

■ an -O-cycloalkyl group, an -O-aryl group or an -O-heterocycloalkyl group, each optionally substituted by

- an aryl group, itself optionally substituted by one or more halogen atom(s) or by a (C_1-C_6) alkyl group,
- an oxo group,
- one or more halogen atom(s), and/or
- a (C_1-C_6) alkyl group, which can itself be substituted by an aryl group and/or an oxo group,

■ an –NH-CO-NH-aryl group, an –NH-CO-NH-heteroaryl group or an –NH-CO-NH-(C_1-C_6) alkyl group, each optionally being substituted by one or more halogen atom(s), by a cyano group, by a nitro group, by one or more hydroxyl group(s) or by a (C_1-C_6) alkoxy group,

■ an –N-(C_1-C_6) alkyl group, it being possible for the (C_1-C_6) alkyl group to be substituted by

- one or more oxo group(s), and/or
- one or more aryl group(s) optionally substituted by one or more halogen atom(s) and/or by an SO_2 group,

■ an –NH-CO-aryl group or an -NH-CO-heteroaryl group, each optionally being substituted by one or more halogen atom(s);

or else R_3 forms, with A, a polycyclic heteroaryl group optionally substituted by a (C_1-C_6) alkoxy group or a (C_1-C_6) alkyl group optionally substituted by an aryl group which can itself be substituted by one or more halogen atom(s);

— R_4 represents a hydrogen atom, an oxo group or a (C_1-C_6) alkyl group;

— Rb represents:

. a hydrogen atom,

. a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s), by

one or more hydroxyl, cyano, amino, heterocycloalkyl or (C_1-C_6) alkoxy group(s) or by an aryl group optionally substituted by one or more halogen atom(s),

. a (C_3-C_6) cycloalkyl group,

. a (C_2-C_6) alkynyl group,

. a (C_1-C_6) alkoxy group,

. an aryl group optionally substituted by one or more halogen atom(s);


— Rc represents a hydrogen atom or a (C_1-C_6) alkyl group optionally substituted by one or more halogen atom(s);

or then Rb and Rc form, together with the nitrogen atom to which they are attached, a polycyclic heteroaryl group or a heterocycloalkyl group;

— m and n represent, independently of one another, the value 0, 1 or 2, it being understood that $m+n \leq 3$;

— p and p' represent, independently of one another, the value 1, 2 or 3, it being understood that, when p is greater than or equal to 2, then the R_2 groups are on separate carbon atoms and can be different from one another and, when p' is greater than or equal to 2, then the R_3 groups are on separate carbon atoms and can be different from one another;

— q represents the value 0 or 2, it being understood that, when q = 0, then the nitrogenous heterocyclic group attached to the nitrogen situated in the 1 position of the 2,4-dioxo-1,2,3,4-tetrahydroquinazoline ring system is no longer bridged and is of the type:



with R_1, R_4, m and n as defined above,

— r represents the value 0 or 1;

in the form of the base or of an addition salt with an acid;

in the treatment and/or prevention of disorder(s) related to the central nervous

system and/or related to the peripheral nervous system, the said disorder(s) being advantageously chosen from psychiatric disorders and neurological disorders.

21. Compound according to the preceding claim, characterized in that it is defined according to any one of Claims 9 to 19.